日本臨牀　69/増刊4　新時代のウイルス性肝炎学

出版社： 日本臨牀社
発行日： 2011-05-20
分野： 臨床医学：一般  >  雑誌
ISSN： 471852
雑誌名：
特集： 新時代のウイルス性肝炎学―基礎・臨床研究の進歩―
電子書籍版： 2011-05-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,400 円(税込)

購入する

目次

  • 日本臨牀　69/増刊4　新時代のウイルス性肝炎学

    ―目次―

    特集　新時代のウイルス性肝炎学―基礎・臨床研究の進歩―

    ?． 総　論
    　１． ウイルス性肝炎研究の変遷・進歩と展望 　
    　２． 我が国における肝炎対策の現況と展望 　

    II． C型肝炎 　 　
    　１． 我が国におけるC型肝炎の疫学─国際比較を含めて─ 　
    　２． C型肝炎の自然経過 　
    　３． C型肝炎ウイルス研究の進歩 　 　
    　４． C型肝炎ウイルス感染における免疫応答と感染防御機構 　 　５． C型肝炎ウイルス関連検査法とその臨床的意義 　
    　６． C型肝炎ウイルス感染とその予防対策 　 　
    　７． HCV感染にかかわる病態 　 　
    　８． Normal serum ALT治療の工夫 　
    　９． C型急性肝炎の動向と診断・治療 　
    　10． 慢性C型肝炎の病理 　
    　11． C型慢性肝炎に対する治療学の進歩 　
    　12． 特殊な病態におけるC型肝炎に対する対応 　 　

    III． B型肝炎 　 　
    　１． 我が国におけるB型肝炎の疫学―国際比較を含めて― 　
    　２． B型肝炎の自然経過 　
    　３． B型肝炎ウイルス研究の進歩 　
    　４． B型肝炎ウイルス感染における免疫応答と感染防御機構 　
    　５． B型肝炎ウイルス関連検査法とその臨床的意義　
    　６． B型肝炎ウイルス感染とその予防対策 　
    　７． B型肝炎の病態 　
    　８． HBV無症候性キャリアの臨床的特徴,マネージメントのあり方 　
    　９． B型急性肝炎の動向と診断・治療 　
    　10． B型劇症肝炎の動向と診断・治療　
    　11． B型慢性肝炎 　
    　12． B型慢性肝炎に対する治療学の進歩 　
    　13． 特殊な病態におけるB型肝炎に対する対応　
    　14． B型肝硬変・B型肝癌

    IV． A型肝炎 　 　
    　１． 我が国におけるA型肝炎の疫学と最近の動向
    　２． A型肝炎ウイルスのウイルス学的特徴
    　３． 近年のA型肝炎：臨床的特徴

    ?． E型肝炎 　 　
    　１． 我が国におけるE型肝炎の疫学と最近の動向
    　２． E型肝炎ウイルスのウイルス学的特徴
    　３． E型肝炎の診断と治療

    VI． デルタ(D型)肝炎 　 　
    　1． デルタ(D型)肝炎:総論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

II C型肝炎

P.21 掲載の参考文献
1) Choo QL et al:Isolation of a cDNA clone derived from a blood-born non-A, non-B viral hepatitis genome. Science 244:359-362, 1989.
 
2) Kuo G, et al:An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364, 1989.
 
3) Weiner AJ, et al:Detection of hepatitis C virus sequences in non-A, non-B hepatitis. Lancet 335:1-3, 1990.
 
4) Okamoto H, et al:Detection of hepatitis C virus RNA by two-stage polymerase chain reaction with two pairs of primers deduced from the 5'non-coding region. Jpn J Exp Med 60:215-222, 1990.
 
5) Watanabe J, et al:Predictive value of screening tests for persistent hepatitis C virus infection evidenced by viraemia. Japanese experience. Vox Sang 65:199-203, 1993.
PubMed
6) 日本赤十字社輸血後肝炎の防止に関する特定研究班:輸血後ウイルス肝炎の現状 1993-1995.研究報告書, 1993-1995, p7-14, 1996.
 
7) World Health Organization:Hepatitis C(Global Alert and Response, 2002), World Health Organization, Geneva, 2002. (http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.html)
 
8) 厚生労働省大臣官房統計情報部:平成20年人口動態統計, 上巻, 財団法人厚生統計協会, 2008.
 
9) 日本肝癌研究会:第5回～第18回全国原発性肝癌追跡調査報告, 日本肝癌研究会事務局, 1982-2009.
 
10) 田中純子ほか:初回供血者集団(1995～2000年献血群, 2001～2006年献血群)を対象とした解析.肝炎ウイルス検診受診者(2002.4-2007.3受診群)を対象とした解析.平成19年度厚生労働科学研究費補助金肝炎等克服緊急対策研究事業肝炎状況・長期予後の疫学に関する研究報告書, p1-9, 2008.
 
11) Tanaka J, et al:Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology, 2011, (in press).
 
12) Tanaka J, et al:Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 47:32-40, 2004.
 
13) Mizui M, et al:Liver disease in hepatitis C virus carriers identified at blood donation and their outcomes with or without interferon treatment:Study on 1019 carriers followed for 5-10 years. Hepatol Res 37:994-1001, 2007.
 
14) Tanaka J, et al:Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 70:378-386, 2003.
 
15) Lavanchy D:The global burden of hepatitis C. Liver Int 29(Suppl 1):74-81, 2009.
PubMed
P.27 掲載の参考文献
1) Healey CJ, et al:Liver histology in hepatitis C virus infection:a comparison between patients with persistently normal or abnormal transaminase. Gut 37:274-278, 1993.
PubMed
2) Puoti C, et al:Hepatitis C virus carriers with persistently normal aminotransferase levels:healthy people or true patients? Dig Dis Sci 32:634-643, 2000.
 
3) Persico M, et al:Hepatitis C virus carriers with persistently normal ALT levels:biological peculiarities and update of the natural history of liver disease at 10 years. J Viral Hepat 13:290-296, 2006.
PubMed
4) Puoti C, et al:Clinical, histological, and viological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 26:1393-1398, 1997.
PubMed
5) Renou C, et al:Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 51:585-590, 2002.
PubMed
6) Okanoue T, et al:A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 5:599-605, 2005.
PubMed
7) Uto H, et al:Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan. J Gastroenterol 42:673-680, 2007.
 
8) Feucht HH, et al:High rate of chronicity in HCV infection determined by antibody confirmatory assay and PCR in 4110 patients during long-term follow up. J Clin Virol 13:43-51, 1999.
PubMed
9) Kondili LA, et al:Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population, Gut 50:693-696, 2002.
PubMed
10) Micallef JM, et al:Spontaneous viral clearance following acute hepatitis C infection:a systematic review of longitudinal studies. J Viral Hepat 13:34-41, 2006.
PubMed
11) Hattori Y, et al:Loss of hepatitis C virus RNA after parturition in female patients with chronic HCV infection. J Med Virol 71:205-211, 2003.
PubMed
12) Yokosuka O, et al:Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases:analysis of HCV RNA in 320 patients who were followed for more than 3 years. J Hepatol 31:394-399, 1999.
PubMed
13) Yoshikawa M, et al:Spontaneous elimination of serum HCV-RNA after total gastrectomy for early gastric cancer in a patient with chronic hepatitis C. Am J Gastroenterol 96:922-923, 2001.
 
14) Fukuizumi K, et al:Natural disappearance of serum HCV RNA:prospective study in a hyperendemic area. Hepatol Res 9:144-151, 1997.
 
15) Uto H, et al:Spontaneous elimination of hepatitis C virus RNA in individuals with persistent infection in a hyperendemic area of Japan. Hepatol Res 34:28-34, 2006.
 
16) Watanabe H, et al:Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers:a population-based study. J Med Virol 71:56-61, 2003.
PubMed
17) Ge D, et al:Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401, 2009.
PubMed
18) Suppiah V, et al:IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 41:1100-1104, 2009.
 
19) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
 
20) Thomas D, et al:Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801, 2009.
PubMed
21) Castillo I, et al:Occult hepatitis C virus infection in patients in whom the etiology of persistent abnormal results of liver-function tests is unknown. J Infect Dis 189:7-14, 2004.
 
22) Carreno V:Occult hepatitis C virus infection:a new form of hepatitis C. World J Gastroenterol 12:6922-6925, 2006.
PubMed
23) Pham TN, et al:Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78:5867-5874, 2004.
 
24) Saito T, et al:Genetic variations in humans associated with differences in the course of hepatitis C. Biochem Biophys Res Commun 317(2):335-341, 2004.
PubMed
25) Kimura T, et al:Association of transforming growth factor(TGF)-β1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis 193:1371-1374, 2006.
 
26) Tanaka H, et al:Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase levels at donation and interaction with hepatitis B virus. Int J Cancer 112:1075-1080, 2004.
 
27) Suruki R, et al:Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer 119:192-195, 2006.
 
28) Nagao Y, et al:The prognosis for life in an HCV hyperendemic area. Gastroenterology 125:628-629, 2003.
 
29) Nagao Y, et al:Acohort study of chronic liver disease in an HCV hyperendemic area of Japan:a prospective analysis for 12 years. Int J Mol Med 13:257-265, 2004.
 
30) Uto H, et al:Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 50:393-399, 2009.
 
P.33 掲載の参考文献
1) Choo QL, et al:Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362, 1989.
 
2) Lohmann V, et al:Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113, 1999.
 
3) Wakita T, et al:Production of infectious hepatitis C virus in tissue cell culture from a cloned viral genome. Nat Med 11:791-796, 2005.
PubMed
4) Mercer DF, et al:Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7:927-933, 2001.
PubMed
5) Ge D, et al:Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401, 2009.
PubMed
6) Suppiah V, et al:IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104, 2009.
PubMed
7) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
8) Fellay J, et al:ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464:405-408, 2010.
PubMed
9) Pileri P, et al:Binding of hepatitis C virus to CD81. Science 282:938-941, 1998.
PubMed
10) Miyanari Y, et al:The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9:1089-1097, 2007.
PubMed
11) Bissig KD, et al:Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 120:924-930, 2010.
 
12) Koike K et al:Animal models for hepatitis C and related liver disease. Hepatol Res 40:69-82, 2010.
PubMed
13) Kriegs M, et al:The hepatitis C Virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo. J Biol Chem 284:28343-28351, 2009.
PubMed
14) Moriya K, et al:Tacrolimus ameliorates metabolic disturbance and oXidative stress caused by hepatitis C virus core protein:analysis using mouse model and cultured cells. Am J Pathol 175:1515-1524, 2009.
PubMed
15) Shiffmann M, et al:PEG-IFN-λ:antiviral activity and safety profile in a 4-week phase 1B study in relapsed genotype 1 hepatitis C infection. J Hepatol 50(Suppl 1):S237, 2009.
 
P.40 掲載の参考文献
1) Simmonds P, et al:Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973, 2005.
PubMed
2) 田中靖人, 溝上雅史:【肝炎ウイルスの遺伝子型】 Hepatitis C virus. 肝臓 46:480-485, 2005.
 
3) Pybus OG, et al:Investigating the endemic transmission of the hepatitis C virus. Int J Parasitol 37:839-849, 2007.
PubMed
4) 溝上雅史, 大羽健一:C型肝炎ウイルスのgenotypeとその分岐時間. 日本臨牀 51(2):304-311, 1993.
Medical*Online
5) Pybus OG, et al:The epidemic behavior of the hepatitis C virus. Science 292:2323-2325, 2001.
PubMed
6) Nakano T, et al:Viral gene sequences reveal the variable history of hepatitis C virus infection among countries. J Infect Dis 190:1098-1108, 2004.
PubMed
7) Tanaka Y, et al:Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 130:703-714, 2006.
PubMed
8) Drummond AJ, et al:Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol 22:1185-1192, 2005.
PubMed
9) Drummond AJ, Rambaut A:BEAST:Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 7:214, 2007.
PubMed
10) Pybus OG, et al:The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt:a Bayesian coalescent approach. Mol Biol Evol 20:381-387, 2003.
PubMed
11) Nakano T, et al:Population genetic history of hepatitis C virus 1b infection in China. J Gen Virol 87:73-82, 2006.
 
12) Markov PV, et al:Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa. J Gen Virol 90:2086-2096, 2009.
 
13) Pepin J, et al:Risk factors for hepatitis C virus transmission in colonial Cameroon. Clin Infect Dis 51:768-776, 2010.
PubMed
14) Verbeeck J, et al:Investigating the origin and spread of hepatitis C virus genotype 5a. J Virol 80:4220-4226, 2006.
PubMed
15) Pybus OG, et al:Genetic history of hepatitis C virus in East Asia. J Virol 83:1071-1082, 2009.
PubMed
P.45 掲載の参考文献
1) Choo QL, et al:Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362, 1989.
 
2) Kato N, et al:Molecular cloning of the hulnan hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87:9524-9528, 1990.
 
3) Suzuki T, et al:Hepatitis C viral life cycle. Adv Drug Deliv Rev 59:1200-1212, 2007.
PubMed
4) Kato N, et al:Genetic variation and dynamics of hepatitis C virus replicons in long-term cell culture. J Gen Virol 86:645-656, 2005.
PubMed
5) Lanford RE, et al:Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201, 2010.
PubMed
6) Sharma SD:Hepatitis C virus:molecular biology & current therapeutic options. Indian J Med Res 131:17-34, 2010.
PubMed
7) Miyanari Y, et al:The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9:1089-1097, 2007.
PubMed
8) Moriya K, et al:The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065-1067, 1998.
PubMed
9) Dubuisson J:Hepatitis C virus proteins. World J Gastroenterol 13:2406-2415, 2007.
PubMed
10) Moradpour D, et al:Replication of hepatitis C virus. Nat Rev Microbiol 5:453-463, 2007.
PubMed
11) Carrere-Kremer S, et al:Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 76:3720-3730, 2002.
PubMed
12) Pietschmann T, et al:Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 103:7408-7413, 2006.
PubMed
13) Li XD, et al:Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 102:17717-17722, 2005.
PubMed
14) Gouttenoire J, et al:Amphipathic alpha-helix AH2 is a major determinant for the oligomerization of hepatitis C virus nonstructural protein 4B. J Virol 84:12529-12537, 2010.
PubMed
15) Tanaka T, et al:A novel sequence found at the 3'-terminus of hepatitis-C virus genome. Biochem Biophys Res Commun 215:744-749, 1995.
 
P.51 掲載の参考文献
1) Tani H, et al:Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol 81:8601-8612, 2007.
PubMed
2) Bartosch B, Cosset F-L:Studying HCV cell entry with HCV pseudoparticles (HCVpp). In:Hepatitis C:Methods and Protocols, 2nd ed, vol.510 (ed by Tang H), p279-293, Human Press, a part of Springer Science + Business Media, Madrid, 2009.
 
3) Wakita T, et al:Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796, 2005.
PubMed
4) Lindenbach BD, et al:Complete replication of hepatitis C virus in cell culture. Science 309:623-626, 2005.
PubMed
5) Tanaka Y, et al:Establishment of an indicator cell system for hepatitis C virus. Microbiol Immunol 54:206-220, 2010.
PubMed
6) Jones CT, et al:Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol 28:167-171, 2010.
PubMed
7) Steinmann E, et al:Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J Virol 82:7034-7046, 2008.
PubMed
8) Ishii K, et al:Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins. Biochem Biophys Res Commun 371:446-450, 2008.
PubMed
9) Burlone ME, Budkowska A:Hepatitis C virus cell entry:role of lipoproteins and cellular receptors. J Gen Virol 90:1055-1070, 2009.
PubMed
10) Rocha-Perugini V, et al:The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS ONE 3:e1866, 2008.
PubMed
11) Farquhar MJ, et al:Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virol 82:8797-8811, 2008.
 
12) Berger KL, et al:Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci USA 106:7577-7582, 2009.
PubMed
13) Mee CJ, et al:Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology 138:1134-1142, 2010.
 
14) Silvie O, et al:Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat Med 9:93-96, 2003.
PubMed
15) Yalaoui S, et al:Scavenger receptor BI boosts hepatocyte permissiveness to Plasmodium infection. Cell Host Microbe 4:283-292, 2008.
PubMed
P.57 掲載の参考文献
1) Lohmann V, et al:Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113, 1999.
 
2) Wakita T, et al:Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11(7):791-796, 2005.
PubMed
3) Sakamoto N, Watanabe M:New therapeutic approaches to hepatitis C virus. J Gastroenterol 44:643-649, 2009.
PubMed
4) Gosert R, et al:Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 77:5487-5492, 2003.
 
5) Aizaki H, et al:Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 324:450-461, 2004.
PubMed
6) Miyanari Y, et al:The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9(9):1089-1097, 2007.
PubMed
7) Nakagawa M, et al:Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313:42-47, 2004.
PubMed
8) Nakagawa M, et al:Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 129(3):1031-1041, 2005.
PubMed
9) Simmonds P, et al:A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321, 1994.
 
10) Enomoto N, et al:Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334(2):77-81, 1996.
PubMed
11) Watanabe H, et al:Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 183:1195-1203, 2001.
PubMed
12) Nakagawa M, et al:Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. J Gastroenterol 45(6):656-665, 2010.
PubMed
13) El-Shamy A, et al:Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:38-47, 2008.
PubMed
14) Akuta N, et al:Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 46(5):1357-1364, 2007.
PubMed
15) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1100-1104, 2009.
 
16) Thomas DL, et al:Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801, 2009.
PubMed
17) Watanabe H, et al:Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection. Virology 311:376-383, 2003.
PubMed
18) Maekawa S, et al:Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficacy in Huh-7 cells. J Viral Hepat 11:394-403, 2004.
 
19) Kohashi T, et al:Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat 13(9):582-590, 2006.
PubMed
P.62 掲載の参考文献
1) Wakita T, et al:Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796, 2005.
PubMed
2) Aizaki H, et al:Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol 82:5715-5724, 2008.
PubMed
3) Simons K, Ikonen E:Functional rafts in cell membranes. Nature 387:569-572, 1997.
PubMed
4) Lohmann V, et al:Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113, 1999.
 
5) Shi ST, et al:Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with caveolin-2. J Virol 77:4160-4168, 2003.
PubMed
6) Egger D, et al:Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76:5974-5984, 2002.
PubMed
7) Aizaki H, et al:Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 324:450-461, 2004.
PubMed
8) Sakamoto H, et al:Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 1:333-337, 2005.
 
9) Gao L et al:Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J Virol 78:3480-3488, 2004.
 
10) Miyanari Y, et al:The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9:1089-1097, 2007.
PubMed
11) Masaki T, et al:Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 82:7964-7976, 2008.
PubMed
12) Herker E, et al:Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat Med 16:1295-1298, 2010.
PubMed
13) Okamoto K, et al:Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation. J Virol 82:8349-8361, 2008.
PubMed
14) Huang H, et al:Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 104:5848-5853, 2007.
PubMed
15) Sezaki H, et al:An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 52:43-48, 2009.
PubMed
P.68 掲載の参考文献
1) McGivern DR, Lemon SM:Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol 4:399-415, 2009.
PubMed
2) Moriya K, et al:The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065-1067, 1998.
PubMed
3) Moriishi K, et al:Critical role of PA28 gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 104:1661-1666, 2007.
 
4) Herzer K, et al:Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. Cancer Res 65:10830-10837, 2005.
PubMed
5) Munakata T, et al:Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 3:1335-1347, 2007.
PubMed
6) Ariumi Y, et al:DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication. J Virol 81:13922-13926, 2007.
PubMed
7) Chang PC, et al:DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control. Oncogene 25:1991-2003, 2006.
PubMed
8) Huang H, et al:Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 130:1679-1687, 2006.
PubMed
9) Jopling CL, et al:Modulation of hepatitis C virus RNA abundance by a liver - specific microRNA. Science 309:1577-1581, 2005.
PubMed
10) Bai S, et al:MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to Sorafenib. J Biol Chem 284:32015-32027, 2009.
PubMed
11) Pedersen IM, et al:Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919-922, 2007.
PubMed
12) Miyaji K, et al:Overexpression of a DEAD box/RNA helicase protein, rck/p54, in human hepatocytes from patients with hepatitis C virus-related chronic hepatitis and its implication in hepatocellular carcinogenesis. J Viral Hepat 10:241-248, 2003.
PubMed
13) Jangra RK, et al:DDX 6(Rck/p54) is required for efficient hepatitis C virus replication but not IRES-directed translation. J Virol 84:6810-6824, 2010.
 
14) Banaudha K, et al:MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology 53:53-61, 2011.
PubMed
15) Furutani T, et al:Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130:2087-2098, 2006.
PubMed
P.73 掲載の参考文献
1) Kato T, et al:Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817, 2003.
PubMed
2) Wakita T, et al:Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796, 2005.
PubMed
3) Zhong J, et al:Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102:9294-9299, 2005.
PubMed
4) Kato T, et al:Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology 48:732-740, 2008.
 
5) Akazawa D, et al:CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol 81:5036-5045, 2007.
PubMed
6) Arnaud N, et al:Hepatitis C virus controls interferon production through PKR activation. PLoS One 5:e10575, 2010.
PubMed
7) Yi M, et al:Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA 103:2310-2315, 2006.
PubMed
8) Murayama A, et al:The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells. J Virol 81:8030-8040, 2007.
 
9) Murayama A, et al:RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells. PLoS Pathog 6:e1000885, 2010.
PubMed
10) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
11) Morikawa K, et al:The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. J Med Virol 79:714-723, 2007.
PubMed
12) Blanchard E, et al:Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80:6964-6972, 2006.
PubMed
13) Evans MJ, et al:Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805, 2007.
PubMed
14) Ploss A, et al:Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886, 2009.
PubMed
15) Rouille Y, et al:Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 80:2832-2841, 2006.
 
16) Miyanari Y, et al:The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9:1089-1097, 2007.
PubMed
17) Masaki T, et al:Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 82:7964-7976, 2008.
PubMed
18) Ishii K, et al:Trans-encapsidation of hepatitis C virus subgenomic replicon RNA with viral structure proteins. Biochem Biophys Res Commun 371:446-450, 2008.
PubMed
P.79 掲載の参考文献
1) Hsu EC, et al:Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat Biotechnol 21:519-525, 2003.
PubMed
2) Kneteman NM, et al:Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 43:1346-1353, 2006.
PubMed
3) Umehara T, et al:Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun 346:67-73, 2006.
 
4) Inoue K, et al:Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45:921-928, 2007.
PubMed
5) Hiraga N, et al:Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett 581:1983-1987, 2007.
PubMed
6) Vanwolleghem T, et al:Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 47:1846-1855, 2008.
PubMed
7) Meuleman P, et al:Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48:1761-1768, 2008.
PubMed
8) Law M, et al:Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14:25-27, 2008.
PubMed
9) Laporte MG, et al:The discovery of pyrano [3, 4-b] indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity. ChemMedChem 3:1508-1515, 2008.
PubMed
10) Kneteman NM, et al:HCV796:A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49:745-752, 2009.
PubMed
11) Matsumura T, et al:Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 137:673-681, 2009.
PubMed
12) Ohira M, et al:Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 119:3226-3235, 2009.
PubMed
13) Kamiya N, et al:Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. J Gen Virol 91:1668-1677, 2010.
PubMed
14) Ohara E, et al:Elimination of hepatitis C virus by short term NS3 -4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol, 2010. [Epub ahead of print]
 
15) Kimura T, et al:Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. J Gen Virol 89:2108-2113, 2008.
PubMed
16) Yanagi M, et al:Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 94:8738-8743, 1997.
PubMed
17) Wakita T, et al:Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796, 2005.
PubMed
18) Suda G, et al:IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. Virology 407:80-90, 2010.
PubMed
P.85 掲載の参考文献
1) 1000 Genomes Project Consortium;Durbin RM, et al:A map of human genome variation from population-scale sequencing. Nature 467:1061-1073, 2010.
PubMed
2) Barrett JC, et al:Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40:955-962, 2008.
PubMed
3) Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research;Saxena R, et al:Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331-1336, 2007.
PubMed
4) Sladek R, et al:A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-885, 2007.
PubMed
5) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
6) Ge D, et al:Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401, 2009.
PubMed
7) Suppiah V, et al:IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104, 2009.
PubMed
8) Rauch A, et al:Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study. Gastroenterology 138:1338-1345, 2010.
PubMed
9) Thomas DL, et al:Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801, 2009.
PubMed
10) Fellay J, et al:ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464:405-408, 2010.
PubMed
11) Ochi H, et al:ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients. Gastroenterology 139:1190-1197, 2010.
PubMed
12) Sakamoto N, et al:ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res 40:1063-1071, 2010.
 
P.90 掲載の参考文献
1) Rehermann B:Hepatitis C virus versus innate and adaptive immune responses:a tale of coevolution and coexistence. J Clin Invest 119:1745-1754, 2009.
PubMed
2) Kanto T:Virus associated innate immunity in liver. Front Biosci 13:6183-6192, 2008.
PubMed
3) Miyazaki M, et al:Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I. J Med Virol 80:980-988, 2008.
 
4) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
5) Khakoo S, et al:HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872-874, 2004.
PubMed
6) Jinushi M, et al:Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation:impairment in chronic hepatitis C virus infection. J Immunol 170:1249-1256, 2003.
 
7) Ahlenstiel G, et al:Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 138:325-335, 2010.
 
8) Jinushi M, et al:Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 173:6072-6081, 2004.
PubMed
9) Kanto T, et al:Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis 190:1919-1926, 2004.
PubMed
10) Kaimori A, et al:Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin. Virology 324:74-83, 2004.
PubMed
11) Shiina M, Rehermann B:Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 47:385-395, 2008.
PubMed
12) Ebihara T, et al:Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 48:48-58, 2008.
PubMed
13) Takahashi K, et al:Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci USA 107:7431-7436, 2010.
PubMed
14) Honda M, et al:Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139:499-509, 2010.
PubMed
15) Itose I, et al:Involvement of dendritic cell frequency and function in Virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients. J Med Virol 79:511-521, 2007.
PubMed
P.96 掲載の参考文献
1) Wang JH, et al:Modulation of the peripheral T-Cell response by CD4 mutants of hepatitis C virus:transition from a Th1 to a Th2 response. Hum Immunol 64:662-673, 2003.
PubMed
2) Hiroishi K, et al:Differential effect of cytotoxic T lymphocyte variant epitopes on generation and cytotoxicity in chronic hepatitis C virus infection. Hepatol Res 24:91-94, 2002.
PubMed
3) Kaneko T, et al:Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Eur J Immunol 27:1782-1787, 1997.
PubMed
4) Jinushi M, et al:Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 173:6072-6081, 2004.
PubMed
5) Nattermann J, et al:The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol 166:443-453, 2005.
 
6) Gale M Jr, Foy EM:Evasion of intracellular host defence by hepatitis C virus. Nature 436:939-945, 2005.
PubMed
7) Thimme R, et al:A target on the move:innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 69:129-141, 2006.
PubMed
8) Ishii S, Koziel MJ:Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 128:133-147, 2008.
PubMed
9) Jinushi M, et al:Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol 171:5423-5429, 2003.
 
10) Piccioli D, et al:Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 42:61-67, 2005.
PubMed
11) Inokuchi M, et al:Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol 81:619-627, 2009.
PubMed
12) Golden-Mason L, et al:Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 81:9249-9258, 2007.
PubMed
13) Nakamoto N, et al:Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 5:e1000313, 2009.
PubMed
14) Francavilla V, et al:Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection:exploring the immunological mechanisms. Eur J Immunol 34:427-437, 2004.
PubMed
P.101 掲載の参考文献
1) Moriya K, et al:The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065-1067, 1998.
PubMed
2) Kasama Y, et al:Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 116:4926-4933, 2010.
 
3) Moradpour D, et al:Replication of hepatitis C virus. Nat Rev Microbiol 5(6):453-463, 2007.
PubMed
4) Moriishi K, et al:Proteasome activator PA28 gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J Virol 77(19):10237-10249, 2003.
 
5) Fukutomi T, et al:Hepatitis C virus core protein stimulates hepatocyte growth:correlation with upregulation of wnt-1 expression. Hepatology 41:1096-1105, 2005.
PubMed
6) Machida K, et al:Hepatitis C virus-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol 82:6711-6720, 2008.
PubMed
7) Rosa D, et al:Activation of naive B lymphocytes via CD81, a pthogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 102:18544-18549, 2005.
PubMed
8) Huang L, et al:Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J Biol Chem 280:36417-36428, 2005.
PubMed
9) Watashi K, et al:Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282-1288, 2003.
PubMed
10) Choi SH, et al:Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular IkappaB kinase. Mol Cell Biol 26:3048-3059, 2006.
PubMed
11) Munakata T, et al:Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci USA 102:18159-18164, 2005.
PubMed
12) Munakata T, et al:Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 3:1335-1347, 2007.
PubMed
13) Tsukiyama-Kohara K, et al:Activation of the CKI-cdk-Rb-E2 F pathway in full-genome hepatitis C virus expressing cells. J Biol Chem 279(15):14531-14541, 2004.
 
14) Nisimura T, et al:Hepatitis C virus impairs p53 via persistent over-expression of 3β-hydroxysterol Δ24-reductase. J Biol Chem 284:36442-36452, 2009.
 
15) Walters K-A, et al:Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog 5:e1000269, 2009.
PubMed
P.107 掲載の参考文献
1) Kukihara H, et al:Human VAP-C negatively regulates hepatitis C virus propagation. J Virol 83:7959-7969, 2009.
PubMed
2) Okamoto T, et al:Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 25:5015-5025, 2006.
PubMed
3) Peng L, et al:Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38(FKBP38) and mTOR. J Biol Chem 285:20870-20881, 2010.
PubMed
4) Sakamoto H, et al:Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 1:333-337, 2005.
 
5) Hsu NY, et al:Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811, 2010.
PubMed
6) Moriya K, et al:The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065-1067, 1998.
PubMed
7) Moriishi K, et al:Critical role of PA28 gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 104:1661-1666, 2007.
 
8) Perlemuter G, et al:Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion:a model of viral-related steatosis. FASEB J 16:185-194, 2002.
 
9) Shintani Y, et al:Hepatitis C virus infection and diabetes:direct involvement of the virus in the development of insulin resistance. Gastroenterology 126:840-848, 2004.
PubMed
10) Tanaka N, et al:PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 118:683-694, 2008.
PubMed
11) Moriishi K, et al:Involvement of PA28gamma in the propagation of hepatitis C virus. Hepatology 52:411-420, 2010.
PubMed
12) Korenaga M, et al:Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280:37481-37488, 2005.
PubMed
13) Diamond DL, et al:Proteomic profiling of human liver biopsies:hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 46:649-657, 2007.
PubMed
14) Moriya K, et al:Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein:analysis using mouse model and cultured cells. Am J Pathol 175:1515-1524, 2009.
PubMed
15) Machida K, et al:Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 80:7199-7207, 2006.
PubMed
16) Boudreau HE, et al:Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor beta-dependent manner:a new contributor to HCV-induced oxidative stress. J Virol 83:12934-12946, 2009.
 
17) Tsutsumi T, et al:Proteomics analysis of mito-chondrial proteins reveals overexpression of a mitochondrial protein chaperon, prohibitin, in cells expressing hepatitis C virus core protein. Hepatology 50:378-386, 2009.
 
P.113 掲載の参考文献
1) Enomoto N, et al:There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commum 170:1021-1025, 1990.
 
2) 西口修平:ウイルス学的検査.内科学書第7版(小川聡編), p221-223, 中山書店, 2009.
 
3) Akuta N, et al:Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380, 2005.
PubMed
4) Akuta N, et al:Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b:amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410, 2007.
 
5) Akuta N, et al:Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 78:83-90, 2006.
PubMed
6) Akuta N, et al:Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79:1686-1695, 2007.
PubMed
7) Akuta N, et al:Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 46:1357-1364, 2007.
PubMed
8) Enomoto N, et al:Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. J Clin Invest 96:224-230, 1995.
PubMed
9) Enomoto N, et al:Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81, 1996.
PubMed
10) 坂本穣, 榎本信幸:ウイルス性慢性肝炎:診断と治療の進歩. 日内会誌 97:57-63:2008.
 
P.121 掲載の参考文献
1) Kaito M, et al:Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 75:1755-1760, 1994.
PubMed
2) Choo QL, et al:Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362, 1989.
 
3) Kuo G, et al:An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364, 1989.
 
4) Chiba J, et al:Serodiagnosis of hepatitis C virus(HCV) infection with an HCV core protein molecularly expressed by a recombinant baculovirus. Proc Natl Acad Sci USA 188:4641-4645, 1991.
 
5) Japanese Red Cross Non-A, Non-B Hepatitis Research Group:Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Lancet 338:1040-1041, 1991.
 
6) Inaba S, et al:HCV transmission after receiving anti-c100-negative blood units. Lancet 337:1354, 1991.
PubMed
7) 日本赤十字社輸血後肝炎の防止に関する特定研究班:研究報告書, p7-14, 1993-1995.
 
8) 長田広司ほか:第2世代HCV抗体スクリーニングで陰性の血液の輸血によるC型肝炎の発生率. 肝臓 95:189, 1994.
 
9) 永山亮造ほか:HCV感染早期のHCV抗体陰性時期での献血に由来する輸血後C型肝炎の1例. 肝臓 39:73-76, 1998.
 
10) Mark A, et al:Behavioral and infectious disease risks in young blood donors:implications for recruitment. Transfusion 43:1596-1603, 2003.
 
11) Nubling CM, et al:Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 42:1037-1045, 2002.
PubMed
12) Busch MP, et al:Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases. Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 40:143-159, 2000.
PubMed
13) Glynn SA, et al:International application of the incidence rate/window period model. Transfusion 42:966-972, 2002.
PubMed
14) Schuttler CG, et al:Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet 355:41-42, 2000.
PubMed
15) Weusten JJ, et al:Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 42:537-548, 2002.
 
16) 高橋雅彦:輸血感染症の現状. 血液事業 23:122-127, 2000.
 
17) CDC:Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. MMWR Morb Mortal Wky Rep 43:505-509, 1994.
 
P.126 掲載の参考文献
1) Iitsuka T, et al:Epidemiological survey of Japanese children infected with hepatitis B and C viruses. Hepatol Res 40:878-886, 2010.
 
2) 大戸斉:C型肝炎ウイルス等の母子感染防止に関する研究. 平成18年度総括・分担研究報告書, p1-18, 2007.
 
3) Roberts EA, et al:Maternal-infant transmission of hepatitis C virus infection. Hepatology 36:S106-113, 2002.
PubMed
4) 長田郁夫ほか:肝炎ウイルス. 周産期医学 40, 2010. (in press)
 
5) Pembrey L, et al:The management of HCV infected pregnant women and their children European paediatric Hepatitis C Virus network. J Hepatol 43:515-525, 2005.
PubMed
6) Shiraki K, et al:Guidelines for care of pregnant women carrying hepatitis C virus and their infants. Pediatr Int 50:138-140, 2008.
PubMed
7) Ackerman, et al:Intrafamilial transmission of hepatitis C virus:a systematic review. J Viral Hepat 7:93-103, 2000.
PubMed
8) Okamoto M, et al:Prospective re-evaluation of risk factors in mother-to-child transmission of hepatitis C virus:high virus load, vaginal delivery and negative anti-NS4 antibody. J Infect Dis 182:1511-1514, 2000.
 
9) European Paediatric Hepatitis C Virus Network:Three broad modalities in the natural history of vertically acquired hepatitis C infection. Clin Infect Dis 41:45-51, 2005.
PubMed
10) Kaneda T, et al:Detection of maternofetal transfusion by placental alkaline phosphatase levels. J Pediatr 130:730-735, 1997.
 
11) Kage M, et al:Pathology of chronic hepatitis C in children. Hepatology 26:771-775, 1997.
PubMed
12) 日本産科婦人科学会:妊娠中にHCV抗体陽性が判明した場合は? 産婦人科診療ガイドライン-産科編2008, p160-162, 2008. (http://www.jsog.or.jp/)(検索日2009.10.31)
 
13) Mohamed MK, et al:Intrafamilial transmission of hepatitis C in Egypt. Hepatology 42:683-687, 2005.
PubMed
14) Plancoulaine S, et al:Dissection of familial correlations in hepatitis C virus(HCV) seroprevalence suggests intrafamilial viral transmission and genetic predisposition to infection. Gut 57:1268-1274, 2007.
 
15) Tohme RA, et al:Is sexual contact a major mode of hepatitis C virus transmission? Heparology 52:1497-1505, 2010.
 
16) Ackerman Z, et al:Hepatitis C Virus in various human body fluids:a systematic review. Hepatol Res 11:26-40, 1998.
 
17) 藤澤知雄ほか:小児期の肝炎ウイルスに対する治療. 小児科 43:1838-1848, 2002.
 
18) Baker RD, et al:Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. J Clin Gastroentero1 41:111-114, 2007.
 
19) 乾あやのほか:小児科領域におけるC型慢性肝炎に対するペグインターフェロン α2b + リバビリン併用療法の経験. 肝臓 49:386-388, 2008.
 
P.133 掲載の参考文献
1) Poro V, et al:Risk of hepatitis C seroconversion after occupational exposure in health care workers. Am J Infect Control 23:273-277, 1995.
 
2) 古川恵一:針刺し事故(HBV, HCV, HIV感染予防). Medical Practice 25:181-185, 2008.
 
3) Sartori M, et al:Transmission of hepatitis C via blood splash into conjunctiva. Scand J Infect Dis 25:270-271, 1993.
PubMed
4) Ippolito G, et al:Simultaneous infection with HIV and hepatitis C virus following occupational conjunctival blood exposure. JAMA 28:280, 1998.
PubMed
5) Krawczynsky K, et al:Effect of immune globulin on the prevention of experimental hepatitis C virus. J Infect Dis 173:822-828, 1996.
 
6) Alter MJ:Occupational exposure to hepatitis C virus:a dilemma. Infect Control Hosp Epidemiol 15:742-744, 1994.
PubMed
7) Seelf LB:Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis:a National Heart, Lung, and Blood Institute collaborative study. Hepatology 33:455-463, 2001.
 
8) 秋葉隆:日本の透析施設におけるHCV感染に関する実態調査. 透析会誌 27:77-82, 1994.
 
9) 佐藤千史:透析患者におけるC型肝炎の対策. 肝胆膵 57:1005-1011, 2008.
Medical*Online
10) Nakayama E, et al:Low prevalence of anti-hepatitis C virus antibodies in female hemodialysis patients without blood transfusion:a multcenter analysis. J Med Viol 48:284-288, 1996.
 
11) Iwasa Y, et al:Patterns in the prevence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol 12:53-57, 2008.
 
12) European Pediatric Hepatitis C Virus Network:A significant sex - but not elective cesarian section - effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 192:1872-1879, 2005.
 
13) Gibb DM, et al:Mother-to-child transmission of hepatitis C virus:evidence for preventable peripartum transmission. Lancet 56:904 -907, 2000.
 
14) Plukett BA, et al:Elective cesarean delivery to prevent perinatal transmission of hepatitis C virus:a cost-effectiveness analysis. Am J Obtest Gynecol 191:998-1003, 2004.
 
15) C型肝炎ウイルス等の母子感染防止に関する研究班:C型肝炎ウイルス(HCV)キャリア妊婦とその出生児の管理ならびに指導方針. 日児誌 109:78-79, 2005.
 
16) Omata M, et al:Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 338:914-915, 1991.
PubMed
17) Bronowicki Jp, et al:Patient-to-patient transmission of hepatitis C virus during colonoscopy. N Engl J Med 337:237-240, 1997.
PubMed
18) 櫻井幸弘:HBV陽性, HCV陽性患者による内視鏡の汚染状況と強酸性水による洗浄・消毒効果の検討. Gastroenterological Endoscopy 46(10):2312-2318, 2004.
 
19) Couzigou P, et al:Detection of HCV-RNA in saliva of patients with chronic hepatitis C. Gut 34(2 Suppl):s59-60, 1993.
 
P.138 掲載の参考文献
1) Allison ME, et al:Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21:1135-1139, 1994.
 
2) Sheikh MY, et al:Hepatitis C virus infection:molecular pathways to metabolic syndrome. Hepatology 47:2127-2133, 2008.
PubMed
3) Hui JM, et al:Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125:1695-1704, 2003.
PubMed
4) Romero-Gomez M, et al:Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128:636-641, 2005.
PubMed
5) Chen CL, et al:Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection:a follow-up study in Taiwan. Gastroenterology 135:111-121, 2008.
PubMed
6) Arao M, et al:Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis Cvirus. J Gastroenterol 38:355-360, 2003.
 
7) Kawaguchi T, et al:Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165:1499-1508, 2004.
PubMed
8) Kawaguchi T, et al:Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102:570-576, 2007.
PubMed
9) Milner KL, et al:Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 138:932-941, 2010.
PubMed
10) Tardif KD, et al:Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J Virol 76:7453-7459, 2002.
PubMed
11) Houstis N, et al:Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944-948, 2006.
PubMed
12) Shintani Y, et al:Hepatitis C virus infection and diabetes:direct involvement of the virus in the development of insulin resistance. Gastroenterology 126:840-848, 2004.
PubMed
13) Dharancy S, et al:Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 128:334-342, 2005.
PubMed
14) Narita R, et al:Impact of steatosis on insulin secretion in chronic hepatitis C patients. Am J Gastroenterol 102:2173-2180, 2007.
PubMed
15) Kawaguchi T, et al:Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 30:479-486, 2010.
 
P.143 掲載の参考文献
1) Moriya K, et al:Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78:1527-1531, 1997.
PubMed
2) Miyanari Y, et al:The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9:961-969, 2007.
 
3) Moriya K, et al:Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C:Analysis in transgenic mice and humans. Biochem Biophys Res Commun 281:1207-1212, 2001.
PubMed
4) Perlemuter G, et al:Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion:a model of viral-related steatosis. FASEB J 16:185-194, 2002.
 
5) Moriishi K et al:Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 104:1661-1666, 2007.
PubMed
6) Shintani Y, et al:Hepatitis C virus infection and diabetes:direct involvement of the virus in the development of insulin resistance. Gastroenterology 126:840-848, 2004.
PubMed
7) Tsutsumi T, et al:Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 304:415-424, 2002.
 
8) Tsutsumi T, et al:Interaction of hepatitis C virus core protein with retinoid X receptor alpha modu-lates its transcriptional activity. Hepatology 35:937-946, 2002.
 
9) Watashi K, et al:Modulation of retinoid signaling by a cytoplasmic viral protein via sequestration of Sp110b, a potent transcriptional corepressor of retinoic acid receptor, from the nucleus. Mol Cell Biol 23:7498-7509, 2003.
PubMed
10) Dharancy S, et al:Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 128:334-342, 2005.
PubMed
11) Tanaka N, et al:PPAR activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 118:683-694, 2008.
PubMed
12) Waris G, et al:Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 81:8122-8130, 2007.
PubMed
13) Mirandola S, et al:Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130:1661-1669, 2006.
PubMed
14) Castera I, et al:Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52:288-292, 2003.
PubMed
15) Poynard T, et al:Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38:75-85, 2003.
 
P.147 掲載の参考文献
1) Farinati F et al:Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV posi-tive hepatitis. J Hepatol 22:449-456, 1995.
 
2) McKie AT, et al:An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291:1755-1759, 2001.
PubMed
3) Gunshin H, et al:Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388:482-488, 1997.
PubMed
4) McKie AT, et al:A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5:299-309, 2000.
 
5) Donovan A, et al:Positional cloning of zebrafish ferroportinl identifies a conserved vertebrate iron exporter. Nature 403:776-781, 2000.
 
6) Vulple CD, et al:Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 21:195-199, 1999.
 
7) Zoller H, et al:Expression of the duodenal iron transporters divalentmetal tranporter 1 and ferro-portin 1 in iron deficiency and iron overload. Gastroenterology 120:1412-1419, 2001.
 
8) Park CH, et al:Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806-7810, 2001.
 
9) Nemeth E, et al:Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461-2463, 2003.
 
10) Nemth E, et al:Hepcidin regulates cellular iron efnux by binding to ferroportin and inducing its internalization. Science 306:2090-2093, 2004.
 
11) Detivaud L, et al:Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 106:746-748, 2005.
PubMed
12) Theurl I, et al:Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J Infect Dis 190:819-825, 2004.
PubMed
13) Fillebeen C, et al:Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C virus. J Biol Chem 280:9049-9057, 2003.
 
14) Cheng KC, et al:8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G-T and A-C substitutions. J Biol Chem 267:166-172, 1992.
 
15) Kato J, et al:Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 42(10):830-836, 2007.
PubMed
P.155 掲載の参考文献
1) Moriya K et al:Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 11:4365-4370, 2001,
 
2) Okuda M, et al:Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 12:366-375, 2002.
 
3) Otani K, et al:Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 128:96-107, 2005.
PubMed
4) Korenaga M, et al:Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species(ROS) production. J Biol Chem 280:37481-37488, 2005.
PubMed
5) Li Y, et al:Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity. FASEB J 21:2474-2485, 2007.
PubMed
6) Gong G, et al:Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Nad Acad Sci USA 98:9599-9604, 2001.
 
7) Furutani T, et al:Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130:2087-2098, 2006.
PubMed
8) Fujita N, et al:Hepcidin expression in the liver:relatively low level in patients with chronic hepatitis C. Mol Med 13:97-104, 2007.
PubMed
9) Nishina S, et al:Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 134:226-238, 2008.
PubMed
10) Miura K, et al:Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 48:1420-1429, 2008.
PubMed
11) Moriishi K et al:Critical role of PA28γin hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci USA 104:1661-1666, 2007.
 
12) Nishina S, et al:Hepatitis C virus protein and iron overload induce hepatic steatosis through the unfolded protein response in mice. Liver Int 30:683-692, 2010.
PubMed
P.160 掲載の参考文献
1) Prati D, et al:Update definition of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1-9, 2002.
 
2) Okanoue T, et al:A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 43:599-605, 2005.
PubMed
3) Kumada T, et al:Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. J Hepatol 50:729-735, 2009.
 
4) Kumada T, et al:Long-term follow-up of patients with hepatitis C with normal alanine aminotransferase. J Med Virol 81:446-451, 2009.
PubMed
5) Okanoue T, et al:Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet count. Hepatol Res 38:27-36, 2008.
 
6) 岡上武:(2)リバビリン併用ペグ・インターフェロン治療, b. ALT正常値のC型慢性肝炎はどう治療するべきか. 肝炎のインターフェロン治療, up to date 2009(小池和彦編), p 24-30, 日本メディカルセンター, 2008.
 
7) Okanoue T, et al:Predictive value of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C:a Japanese multi-center study. J Gastroenterol 44:952 -963, 2009.
 
8) Puoti C, et al:HCV carriers with normal alanine aminotransferase levels:Healthy persons or severely patients? Dealing with an everyday clinical problem. Eur J Intern Med 21:57-61, 2010.
PubMed
P.164 掲載の参考文献
1) Yano Ket al:Dynamic epidemiology of acute viral hepatitis in Japan. Intervirology 53:70-75, 2010.
 
2) Hofer H, et al:Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 37:60-64, 2003.
PubMed
3) Nomura H, et al:Short-term interferon-alfa therapy for acute hepatitis C:a randomized controlled trial. Hepatology 39:1213-1219, 2004.
PubMed
4) Gerlach JT, et al:Acute hepatitis C:high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125:80-88, 2003.
PubMed
5) Jaeckel E, et al:Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345:1452-1457, 2001.
PubMed
6) Delwaide J, et al:Treatment of acute hepatitis C with interferon alpha-2b:early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 20:15-22, 2004.
PubMed
7) Santantonio T, et al:Efficacy of a 24-week course of PEG」nterferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 42:329-333, 2005.
 
8) Alter HJ:New kit on the block:evaluation of second-generation assays for detection of antibody to the hepatids C virus. Hepatology 15:350-353, 1992.
 
9) Kamal SM, et al:Pegylated interferon alpha therapy in acute hepatitis C:relation to hepatitis C virus-specific T cell response kinetics. Hepatology 39:1721-1731, 2004.
PubMed
10) Kamal SM, et al:Peginterferon alfa-2b therapy in acute hepatitis C:impact of onset of therapy on sustained virologic response. Gastroenterology 130:632-638, 2004.
 
P.170 掲載の参考文献
1) 田中純子ほか:HCV感染の疫学の変化:現状と将来. 肝胆膵 57:707-715, 2008.
 
2) 羽賀博典:C型肝炎の病理診断:移植後症例も含めて. 肝胆膵 57:755-763, 2008.
Medical*Online
3) Charlton M:Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 7:585-602, 2003.
PubMed
4) McCaughan GW, Zekry A:Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 40:368-374, 2004.
PubMed
5) Dixon LR, Crawford JM:Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl 13:219-226, 2007.
PubMed
6) Demetris AJ:Evolution of hepatitis C Virus in liver allografts. Liver Transpl 15(Suppl 2):S35-41, 2009.
PubMed
7) Yoon EJ, Hu KQ:Hepatitis C virus(HCV) infection and hepatic steatosis. Int J Med Sci 3:53-56, 2006.
PubMed
8) Czaja AJ, Carpenter HA:Histological findings in chronic hepatitis C with autoimmune features. Hepatology 26:459-466, 1997.
PubMed
9) Kessel A, Toubi E:Chronic HCV-related autoimmunity:a consequence of viral persistence and lymphotropism. Curr Med Chem 14:547-554, 2007.
PubMed
10) Ichida F, et al:New Inuyama classification:new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 6:112-119, 1996.
 
11) 宮西浩嗣ほか:C型慢性肝炎に対する瀉血療法. 肝胆膵 57:919-924, 2008.
Medical*Online
12) Kaji K, et al:Hemosiderin deposition in portal endothelial cells is a histologic marker predicting poor response to interferon-alpha therapy in chronic hepatitis C. Pathol Int 47:347-352, 1997.
PubMed
13) Kaji K et al:Hemosiderin deposition in portal endothelial cells:a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. Hum Pathol 26:1080-1085, 1995.
 
14) Shibata M, et al:Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 351:1773-1777, 1998.
PubMed
15) Lefkowitch JH, et al:Pathological diagnosis of chronic hepatitis C:a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 104:595-603, 1993.
PubMed
16) Nakanuma Y, Ohta G:Is mallory body formation a preneoplastic change? A study of 181 cases of liver bearing hepatocellular carcinoma and 82 cases of cirrhosis. Cancer 55:2400-2404, 1985.
 
17) Kaji K et al:Hepatitic bile duct injuries in chronic hepatitis C:histopathologic and immunohistochemical studies. Mod Pathol 7:937-945, 1994.
PubMed
18) Zen Y, et al:Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis and chronic viral hepatitis? Interobserver histological agreement on trimmed bile ducts. J Gastroenterol 40:164-170, 2005.
PubMed
19) Fillipowicz EA, et al:Detection of HCV in bile duct epithelium by laser capture microdissection(LCM). In Vivo 19:737-739, 2005.
 
20) Ozaras R, et al:The prevalence of hepatic granulomas in chronic hepatitis C. J Clin Gastroenterol 38:449-452, 2004.
PubMed
21) Harada K, et al:Epithelioid cell granulomas in chronic hepatitis C:immunohistochemical character and histological marker of favourable response to interferon-alpha therapy. Histopathology 33:216-221, 1998.
PubMed
22) Wanless IR, et al:Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 124:1599-1607, 2000.
PubMed
23) Charlton M:Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 7:585-602, 2003.
PubMed
24) Gopal DV, Rosen HR:Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 9:348-353, 2003.
PubMed
P.179 掲載の参考文献
1) Hayashi N, Takehara T:Antiviral therapy for chronic hepatitis C:past, present, and future. J Gastroenterol 41(1):17-27, 2006.
PubMed
2) Ghany MG, et al:Diagnosis, management, and treatment of hepatitis C:an update. Hepatology 49(4):1335-1374, 2009.
PubMed
3) Ge D, et al:Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399-401, 2009.
PubMed
4) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10):1105-1109, 2009.
PubMed
5) Thomas DL, et al:Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265):798-801, 2009.
PubMed
6) Enomoto N, et al:Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81, 1996.
PubMed
7) El-Shamy A, et al:Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48(1):38-47, 2008.
PubMed
8) Akuta N, et al:Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b:amino acid sub-stitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46(3):403-410, 2007.
 
9) McHutchison JG, et al:Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123(4):1061-1069, 2002.
PubMed
10) Oze T, et al:Pegylated interferon alpha-2b(Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. J Viral Hepat 16(8):578-585, 2009.
PubMed
11) Hiramatsu N, et al:Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 16(8):586-594, 2009.
PubMed
12) Berg T, et al:Extended treatment duration for hepatitis C virus type 1:comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130(4):1086-1097, 2006.
PubMed
13) Pearlman BL, et al:Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 46(6):1688-1694, 2007.
PubMed
14) Mangia A, et al:Individualized treatment duration for hepatitis C genotype 1 patients:A randomized controlled trial. Hepatology 47(1):43-50, 2008.
PubMed
15) Inoue Y, et al:Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin:reducing drug doses has no impact on rapid and sus-tained virological responses. J Viral Hepat 17:336-344, 2010.
 
16) Shiffman ML, et al:Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357(2):124-134, 2007.
 
P.183 掲載の参考文献
1) Ikeda K et al:Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C:A long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124-1130, 1999.
 
2) Kawamura Y, et al:Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 120:1034-1041, 2007.
PubMed
3) Arase Y, et al:Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49:739-744, 2009.
PubMed
4) Arase Y, et al:Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol 82:390-395, 2010.
PubMed
5) Manns MP, et al:Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial. Lancet 358:958-965, 2001.
PubMed
6) Fried MW, et al:Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002.
PubMed
7) Hadziyannis SJ, et al:Peginterferon-alpha2 a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355, 2004.
 
8) McHutchison JG, et al:Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123:1061-1069, 2002.
PubMed
9) Katamura Y, et al:Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load. Intern Med 47:1827-1834, 2008.
 
10) Akuta N, et al:Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429, 2010.
PubMed
11) Akuta N, et al:Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b:amino acid sub-stitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410, 2007.
 
12) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
13) Iwasaki Y, et al:Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43:54-63, 2006.
PubMed
14) Sezaki H, et al:Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 54:1317-1324, 2009.
PubMed
15) Akuta N, et al:A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan:amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 81:452-458, 2009.
PubMed
P.187 掲載の参考文献
1) Akuta N, et al:Et6cacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan:therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 37:831-836, 2002.
PubMed
2) Iwasaki Y, et al:A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a in patients infected With chronic hepatitis C virus genotype 2 or low viral load genotype 1:a multicenter national study in Japan. Hepatol Int, 2009. [Epub ahead of print]
PubMed
3) Ghany MG, et al:Diagnosis, management, and treatment of hepatitis C:An update. Hepatology 49:1335-1374, 2008.
 
4) Kumada H, et al:Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 40:8-13, 2010.
PubMed
5) Wedemeyer H, et al:Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. Hepatology 39:1201-1203, 2004.
PubMed
6) Kamal SM:Acute hepatitis C:a systematic review. Am J Gastroenterol 103:1283-1297, 2008.
PubMed
7) Thomas DL, et al:Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801, 2009.
PubMed
8) Kubo S, et al:Effects of long-term postoperative interferon-alpha therapy on intrahepatic recur-rence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134:963-967, 2001.
 
9) Mazzaferro V, et al:Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44:1543-1554, 2006.
PubMed
10) Shiratori Y, et al:Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138:299-306, 2003.
PubMed
11) Papatheodoridis GV, et al:Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis:a meta-analysis. Aliment Pharmacol Ther 15:689-698, 2001.
 
12) Bruno S, et al:Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis:a retrospective study. Hepatology 45:579-587, 2007.
PubMed
13) Yoshida H, et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by lnterferon Therapy. Ann Intem Med 131:174-181, 1999.
 
14) Arase Y, et al:Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 79:1095-1102, 2007.
PubMed
15) Di Bisceglie AM, et al:Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359:2429-2441, 2008.
PubMed
P.195 掲載の参考文献
1) Manns MP, et al:Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial. Lancet 358:958-965, 2001.
PubMed
2) Fried MW, et al:Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002.
PubMed
3) Hadziyannis SJ, et al:Peginterferon-alpha2 a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355, 2004.
 
4) McHutchison JG, et al:Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123:1061-1069, 2002.
PubMed
5) Akuta N, et al:Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429, 2010.
PubMed
6) Akuta N, et al:Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1 b:amino acid sub-stitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410, 2007.
 
7) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
8) Sezaki H, et al:Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 54:1317-1324, 2009.
PubMed
9) Akuta N, et al:A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan:amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 81:452-458, 2009.
PubMed
10) Iwasaki Y, et al:Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43:54-63, 2006.
PubMed
11) Arase Y, et al:Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intervirology 51:1-6, 2008.
PubMed
P.199 掲載の参考文献
1) Ye J, et al:Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 100(26):15865-15870, 2003.
PubMed
2) Ikeda M, et al:Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44(1):117-125, 2006.
PubMed
3) Bader T, et al:Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 103(6):1383-1389, 2008.
PubMed
4) Sakamoto H, et al:Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 1(6):333-337, 2005.
 
5) Sezaki H, et al:An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 52(1):43-48, 2009.
PubMed
6) O'Leary JG, et al:Atorvastatin does not exhibit antiviral activity against HCV at conventional doses:a pilot clinical trial. Hepatology 45(4):895-898, 2007.
 
7) Rao GA, Pandya PK:Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 140:144-152, 2011.
PubMed
8) 河合良成ほか:Teprenone(Selbex)とPlaunotol(Kelnac)のHCV複製抑制効果. 肝臓 50(Suppl 1):A248, 2009.
 
9) 河合良成ほか:抗潰瘍剤によるC型慢性肝炎の新たな治療戦略TeprenoneはStatinのゲラニルゲラニル化阻害を増強しHCV複製抑制効果を増強する. 肝臓 50(Suppl 2):A463, 2009.
 
10) 竹下茂之ほか:Geranylgeranylacetoneの抗HCV作用に関する検討. 肝臓 50(Suppl 1):A248, 2009.
 
11) Inoue K, et al:Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C:controlled trial. J Gastroenterol 38(6):567-572, 2003.
 
12) Watashi K, et al:Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38(5):1282-1288, 2003.
PubMed
13) Nakagawa M, et al:Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313(1):42-47, 2004.
PubMed
14) Paeshuyse J, et al:The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43(4):761-770, 2006.
 
15) Flisiak R, et al:The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47(3):817-826, 2008.
PubMed
16) Inoue K, et al:Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 45(4):921-928, 2007.
PubMed
17) Flisiak R, et al:The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49(5):1460-1468, 2009.
PubMed
18) Korba BE, et al:Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 77(1):56-63, 2008.
PubMed
19) Rossignol JF, et al:Clinical trial:randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 28(5):574-580, 2008.
PubMed
20) Rossignol JF, et al:Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136(3):856-862, 2009.
PubMed
21) Bacon B, et al:Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients:interim analysis shows increase in EVR. J Hepatol 50(Suppl 1):S381, 2009.
 
22) Shiffman M, et al:Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders(NR) with chronic HCV genotype 1:week 28 interim analysis. J Hepatol 50(Suppl 1):S385-S386, 2009.
 
23) Romero-Gomez M, et al:Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 50(6):1702-1708, 2009.
PubMed
24) Ferenci P, et al:Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135(5):1561-1567, 2008.
PubMed
25) Ahmed-Belkacem A, et al:Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 138(3):1112-1122, 2010.
PubMed
26) Wagoner J, et al:Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51(6):1912-1921, 2010.
PubMed
P.205 掲載の参考文献
1) Tomikawa M, et al:Laparoscopic splenectomy may be a superior supportive intervention for cirrhotic patients with hypersplenism. J Gastroenterol Hepatol 25:397 -402, 2010.
 
2) 松本晶博ほか:IFN療法におけるPSEの功罪. 肝胆膵 56:361-366, 2008.
Medical*Online
3) Hayashi PH, et al:Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. J Clin Gastroenterol 40:740-744, 2006.
PubMed
4) 松本晶博ほか:血小板減少例の対策:脾摘. 肝胆膵 57:969-974, 2009.
 
5) 川中博文ほか:IFN療法における脾摘の功罪. 肝胆膵 56:367-376, 2008.
Medical*Online
6) Morihara D, et al:Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. Hepatol Res 39:439-447, 2009.
PubMed
7) 緒方俊郎ほか:肝硬変に対する脾摘の意義と注意点. 外科 72:63-67, 2010.
 
8) Ikezawa K, et al:Splenectomy and antiviral treatment for thrombocytopenic patients with chronic hepatitis C virus infection. J Viral Hepat 17:488-492, 2010.
PubMed
9) Akahoshi T, et al:Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surg Endosc 24:680-685, 2010.
PubMed
10) Foruny JR, et al:Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol 17:1157-1164, 2005.
PubMed
11) Miyake Y, et al:Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatol Res 38:980-986, 2008.
PubMed
12) 田原博貴ほか:血小板低値C型肝炎に対するPSE + IFN療法. 肝胆膵 57:959-967, 2008.
Medical*Online
13) Syed E, et al:Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol 43:1378-1386, 2008.
 
14) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
 
15) McHutchison JG, et al:Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357:2227-2236, 2007.
PubMed
P.210 掲載の参考文献
1) Monazahian M, et al:Binding of human lipoproteins(low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol 188:177-184, 2000.
PubMed
2) Fujiwara K, et al:Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 37:701-710, 2007.
PubMed
3) Yamashita T, et al:Virological effects and safety of combined double filtration plasmapheresis(DFPP) and interferon therapy in patients with chronic hepatitis C:A preliminary study. Hepatol Res 36:167-175, 2006.
PubMed
4) 井出達也ほか:C型慢性肝炎へのIFNα-2b・リバビリン療法における二重濾過血漿交換併用療法の臨床的検討. 日本アフェレシス学会雑誌 25:233-239, 2006.
 
5) Boni C, et al:Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968-975, 1998.
PubMed
6) Asahina Y, et al:A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 34:377-384, 2001.
PubMed
7) Taniguchi M, et al:Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C. Transplantation 81:1747-1749, 2006.
PubMed
P.214 掲載の参考文献
1) Hayashi N, Takehara T:Antiviral therapy for chronic hepatitis C:past, present, and future. J Gastroenterol 41:17-27, 2006.
PubMed
2) Lok AS, et al:Maintenance peginterferon therapy to prevent hepatocellular carcinoma in patients with advanced chronic hepatitis C:extended follow-up results from the HALT-C trial(AASLD 2010 #214). Hepatology 52:112A 2010.
 
3) Ghany MG, et al:Diagnosis, management, and treatment of hepatitis C:an update. Hepatology 49:1335-1374, 2009.
PubMed
4) Poynard T, et al:Peginterferon alfa-2b and ribavirin:effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136:1618-1628, 2009.
PubMed
5) Jensen DM, et al:Re-treatment of patients with chronic hepatitis C who do not respond to peginter-feron-alpha2b:a randomized trial. Ann Intern Med 150:528-540, 2009.
 
6) Pearlman B, Ehleben C:Retreatment of chronic hepatitis C-genotype 1-infected relapsers to peginterferon/ribavirin with consensus interferon/ribavirin or with extended duration therapy peginterferon/ribavirin(AASLD 2009#815). Hepatology 50:175A 2009.
 
7) 竹原徹郎:厚生労働科学研究費補助金肝炎等克服緊急対策事業「C型肝炎難治症例の病態解明と抗ウイルス治療に関する研究」平成21年度総括・分担研究報告書, 2010.
 
8) McHutchison JG, et al:Telaprevir for previously treated chronic HCV infection. N Engl J Med 362:1292-1303, 2010.
PubMed
9) Bacon BR et al:HCV Respond-2 final results:high sustained virologic response among genotype 1 previous non-responder and relapsers to peginterferon/ribavirin when re-tretaed with boceprevir plus peginterferon/ribavirin(AASLD 2010#216). Hepatology 52:112A 2010.
 
10) Fried MW, et al:Efficacy and safety of TMC435 in combination with peginterferonα-2a and ribavirin in treatment-naive genotype-1 HCV patients:24-week interim results from the pillar study(AASLD 2010#LB-5). Hepatology 52:107A, 2010.
 
P.220 掲載の参考文献
1) Arase Y, et al:Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Intern Med 46:1827-1832, 2007.
PubMed
2) Roomer R, et al:Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 52:1225-1231, 2010.
PubMed
3) Ji F-P, et al:Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C. World J Gastroenterol 16:4394-4399, 2010.
PubMed
4) 医薬品・医療機器等安全性情報 No.250 インターフェロン製剤による間質性肺炎について, 2008年9月.
 
5) Tokita H, et al:Circulating KL-6 level at baseline is a predictive indicator for the occurrence of inter-stitial pneumonia during interferon treatment for chronic hepatitis C. Hepatol Res 26:91-97, 2003.
 
6) 重篤副作用疾患別対応マニュアル 間質性肺炎肺臓炎胞隔炎肺線維症, 平成18年11月, 厚生労働省.
 
7) 井出達也ほか:特集インターフェロン 身体疾患とうつ病 各科臨床におけるうつ病診療の実際 インターフェロン治療とうつ病. Progress in Medicine 29:2397-2400, 2009.
 
P.225 掲載の参考文献
1) Iwasaki Y, et al:Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43:54-63, 2006.
PubMed
2) 厚生労働省大臣官房統計情報部:平成21年人口動態統計, 上巻, 財団法人厚生統計協会, 2009.
 
3) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-αand ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
 
4) Kobayashi M, et al:Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 82:41-48, 2010.
PubMed
5) 熊田博光:平成21年度厚生労働省科学研究費補助金肝炎等克服緊急対策研究事業(肝炎分野)肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究総括・分担報告書, 2009.
 
6) Ide T, et al:A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C. Int J Mol Med 11:729-732, 2003.
PubMed
7) Sho Y, et al:Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol 39:1202-1204, 2004.
PubMed
8) Afdhal NH, et al:Epoetin alfa maintains ribavirin dose in HCV-infected patients:a prospective, double-blind, randomized controlled study. Gastroenterology 126:1302-1311, 2004.
PubMed
9) Younossi ZM, et al:A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat 15:370-378, 2008.
PubMed
10) 豊田成司ほか:リバビリンの全身クリアランス(CL/F)は貧血に伴う減量・中止に対する最も感度の高い因子である. 肝臓 46:107-118, 2005.
 
11) Kamar N, et al:Ribavirin pharmacokinetics in renal and liver transplant patients:evidence that it depends on renal function. Am J Kidney Dis 43:140-146, 2004.
PubMed
12) Oze T, et al:Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.JGastroenterol 41:862-872, 2006.
PubMed
13) 堺隆弘ほか:Ro25-8310(ペグインターフェロンアルファー2a)のC型慢性肝炎に対する第II相臨床試験. 医学と薬学 50:655-672, 2003.
 
14) Hayashi K, et al:Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy. J Med Virol 81:459-466, 2009.
PubMed
15) Iwasaki Y, et al:A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1:a multicenter national study in Japan. Hepatol Int 3:468-479, 2009.
PubMed
P.232 掲載の参考文献
1) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
2) Nishida N, et al:Further development of multiplex single nucleotide polymorphism typing method, the DigiTag2 assay. Anal Biochem 364:78-85, 2007.
PubMed
3) Ge D, et al:Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401, 2009.
PubMed
4) Suppiah V, et al:IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104, 2009.
PubMed
5) Akuta N, et al:Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429, 2010.
PubMed
6) Thomas DL et al:Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801, 2009.
PubMed
7) Muir AJ, et al:Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52:822-832, 2010.
PubMed
8) Honda M, et al:Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139:499-509, 2010.
PubMed
P.238 掲載の参考文献
1) Enomoto N, et al:Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81, 1996.
PubMed
2) Enomoto N, et al:Comparison of full-length s equences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96:224-230, 1995.
 
3) El-Shamy A, et al:Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48:38-47, 2008.
PubMed
4) Blight KI, et al:Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974, 2000.
 
5) Maekawa S, et al:Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells. J Viral Hepat 11:394-403, 2004.
 
6) 坂本穣, 榎本信幸:Interferon sensitivity determining region:ISDR. 肝胆膵 57(5):773-779, 2008.
Medical*Online
7) Prouski V, Holmes EC:SWAN:sliding Window analysis of nucleotide sequence variability. Bioinfor-matics 14:467-468, 1998.
 
8) 坂本 穣, 榎本信幸:ウイルス性慢性肝炎:診断と治療の進歩. 日内会誌 97(1):57-63, 2008.
 
9) 坂本 穣, 榎本信幸:遺伝子変異からみたC型慢性肝炎に対するインターフェロン治療効果予測. 日消誌. 106:485-492, 2009.
Medical*Online
10) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-αand ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
 
P.246 掲載の参考文献
1) Akuta N, et al:Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380, 2005.
PubMed
2) Akuta N, et al:Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b:amino acid sub-stitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410, 2007.
 
3) Donlin MJ, et al:Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 81:8211-8224, 2007.
PubMed
4) Okanoue T, et al:Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C:a Japanese multi-center study. J Gastroenterol 44:952-963, 2009.
PubMed
5) Nakamoto S, et al:Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol 44:872-877, 2009.
PubMed
6) Enomoto N, et al:Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. J Clin Invest 96:224-230, 1995.
PubMed
7) Enomoto N, et al:Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81, 1996.
PubMed
8) Shirakawa H, et al:Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48:1753-1760, 2008.
PubMed
9) Ge D, et al:Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401, 2009.
PubMed
10) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
11) Suppiah V, et al:IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104, 2009.
PubMed
12) Akuta N, et al:Amino acid substitution in HCV core region and genetic variation near IL28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429, 2010.
PubMed
13) Akuta N, et al:Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol 82:575-582, 2010.
PubMed
14) Akuta N, et al:Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 46:1357-1364, 2007.
PubMed
15) Akuta N, et al:Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 81:1032-1039, 2009.
PubMed
16) Fishman SL, et al:Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res 15:3205-3213, 2009.
PubMed
17) Ogura S, et al:Virological and biochemical features in elderly HCV patients with hepatocellular carci-noma:amino acid substitutions in HCV core region as predictor of mortality after first treatment. Intervirology 52:179-188, 2009.
 
18) Nakamoto S, et al:Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J Hepatol 52:72-78, 2010.
PubMed
19) Tachi Y, et al:Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int 30:554-559, 2010.
PubMed
20) Kobayashi M, et al:Influence of amino-acid polymorphism in the core protein on progression of Iiver disease in patients infected With hepatitis C virus genotype 1b. J Med Virol 82:41-48, 2009.
 
21) Hu, et al:Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci 100:2465-2468, 2009.
 
22) Moriya K, et al:Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78:1527-1531, 1997.
PubMed
23) Moriya K, et al:The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065-1067, 1998.
PubMed
24) Shintani Y, et al:Hepatitis C virus infection and diabetes:direct involvement of the virus in the development of insulin resistance. Gastroenterology 126:840-848, 2004.
PubMed
P.254 掲載の参考文献
1) Garzotto M, et al:Recursive partitioning for risk stratification in men undergoing repeat prostate Cancer 104(9):1911-1917, 2005.
PubMed
2) Kurosaki M, et al:A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 40(3):251-260, 2010.
 
3) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
4) Ge D, et al:Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399-401, 2009.
PubMed
5) Suppiah V, et al:IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104, 2009.
PubMed
6) Kurosaki M, et al:Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol, 2010. [Epub ahead of print]
 
7) Enomoto N, et al:Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334(2):77-81, 1996.
PubMed
8) Kurosaki M, et al:Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 25(3):750-753, 1997.
 
9) Akuta N, et al:Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48(6):372-380, 2005.
PubMed
10) Okanoue T, et al:Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C:a Japanese multi-center study. J Gastroenterol 44(9):952-963, 2009.
PubMed
11) Kurosaki M, et al:Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin:data mining analysis. J Med Virol 83:445-452, 2011.
PubMed
12) Kurosaki M, et al:Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 54:439-448, 2011.
PubMed
P.260 掲載の参考文献
1) 宮地一馬ほか:慢性肝疾患の肝機能に及ぼすUrsodeoxychol酸の影響- 一施設二重盲験比較対照試験ならびに肝血流に及ぼす影響による検討-. 臨床と研究 53(5):1395-1403, 1976.
 
2) Osuga T, et al:Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Dig Dis Sci 34(Suppl 12):49-51, 1989.
 
3) Takano S, et al:A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 20(3):558-564, 1994.
 
4) Takikawa H, et al:Ursodeoxycholic acid therapy for chronic type C hepatitis:A multicenter, dose-finding trial. Curr Ther Res 55:16-21, 1994.
 
5) Omata M, et al:A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 56(12):1747-1753, 2007.
PubMed
6) 田辺三菱製薬:MT-711(ウルソデオキシコール酸)のC型慢性肝炎に対する長期投与試験(社内資料).
 
7) Matsuzaki Y, et al:Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 85:15-23, 1990.
PubMed
8) Tarao K, et al:Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. Cancer Epidemiol Biomarkers Prev 14(1):164-169, 2005.
PubMed
9) Ikegami T, et al:The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats:suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 134:129-139, 1998.
PubMed
10) 鈴木宏ほか:強力ミノファーゲンCの慢性肝炎に対する治療効果について -二重盲検法による検討-. 医学のあゆみ 102(8):562, 1977.
 
11) Iino S, et al:Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res 19(1):31-40, 2001.
 
12) Tsubota A, et al:Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection:a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol 11:1077-1083, 1999.
PubMed
13) Ikeda K, et al:A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C:a cohort study of 1249 patients. Dig Dis Sci 51(3):603-609, 2006.
 
14) 熊田博光:「C型肝炎ウイルスの感染者に対する治療の標準化に関する臨床的研究」肝炎等克服緊急対策研究事業 平成13年度～15年度 総合研究報告書, 2004.
 
P.265 掲載の参考文献
1) Isomura T, et al:Excess iron in the liver of patients with chronic hepatitis C. J Clin Electron Microsc 25:231-237, 1992.
 
2) Hayashi H, et al:Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 89:986-988, 1994.
 
3) Piperno A, et al:Iron stores, response to alpha-interferon therapy and effects of iron depletion in chronic hepatitis C. Liver 16:248-254, 1996.
PubMed
4) Bonkovsky HL et al:Iron and chronic viral hepatitis. Hepatology 25:759-768, 1997.
PubMed
5) Bonkovsky HL:Therapy of hepatitis C:Other options. Hepatology 26(Suppl 1):143S-151S, 1997.
PubMed
6) Bassett SE, et al:Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology 29:1884-1892, 1999.
PubMed
7) 松本匡史ほか:C型慢性肝炎に対する食事性の鉄摂取制限の有効性. 肝臓 40:436-444, 1999.
 
8) 林久男:鉄の細胞毒性とC型慢性肝炎での役割. 肝臓 40:431-435, 1999.
 
9) Kato J, et al:Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61:8697-8702, 2001.
PubMed
10) Kato J, et al:Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 42:830-836, 2007.
PubMed
11) Yano M, et al:A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C:a multicenter prospective randomized controlled trial in Japan. J Gastroenterol 39:570-574, 2004.
 
12) Yano M, et al:Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 97:133-137, 2002.
PubMed
13) Wakusawa S, et al:Combined phlebotomy and ursodeoxycholic acid treatment in the patients with chronic hepatitis C. Hepatol Res 18:54-62, 2000.
 
14) 角田圭雄ほか:C型慢性肝炎に対するグリチルリチン製剤静脈内投与前の少量間欠瀉血療法の有用性について. 日本消化器病学会誌 104:1044-1050, 2007.
 
15) Tanaka N, et al:Efficacy and safety of addition of minor bloodletting(petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections. J Gastroenterol 44:577-582, 2009.
PubMed
P.273 掲載の参考文献
1) Suzuki F, et al:Sustained Virological response in a patients with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir. J Clin Virol 47:76-78, 2009.
 
2) Ozeki I:Outcome of peginterferon alfa-2b and ribavirin therapy following MP-424(telaprevir) monotherapy for 24 weeks in Japanese patients With chronic hepatitis C Virus genotype 1b infection. J Hepatol 52:S295, 2010.
 
3) Reesink HW, et al:Rapid decline of viral RNA in hepatitis C patients treated with VX-950:a phase Ib, placebo controlled, randomized study. Gastroenterology 131:997-1002, 2006.
PubMed
4) Sarrazin C, et al:Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with protease inhibitor telaprevir. Gastroenterology 132:1767-1777, 2007.
PubMed
5) Forestier N, et al:Antiviral activity of telaprevir(VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46:640-648, 2007.
PubMed
6) Suzuki F, et al:Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir(MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 39:1056-1063, 2009.
PubMed
7) Tanaka Y, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
8) Akuta N, et al:Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380, 2005.
PubMed
9) Akuta N, et al:Amino acid substitution in hepatitis C virus core region and genetic variation near interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429, 2010.
PubMed
10) Berg T, et al:SVR with telaprevir, peginterferon alfa-2a and ribavirin in HCV patients with wellcharacterized prior null response, partial response, viral breakthrough or relapse after PR:Rollover Study 107. J Hepatol 52:S2, 2010.
 
P.280 掲載の参考文献
1) Kwo PY, et al:Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-nalve patients with genotype 1 hepatitis C infection(SPRINT-1):an open-label, randomized, multicentre phase 2 tria1. Lancet 376:705-716, 2010.
 
2) Le Pogam S, et al:RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus(HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis 202:1510-1519, 2010.
 
3) Gao M, et al:Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100, 2010.
PubMed
4) Gane EJ, et al:Oral combination therapy with nucleoside polymerase inhibitor(RG7128) and danoprevir for chronic hepatitis C genotype 1 infection(INFORM-1):a randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1441-1442, 2010.
 
5) Flisiak R, et al:The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces Viral load in treatment-naive hepatitis C patients. Hepatology 49:1460-1468, 2009.
PubMed
6) Rossignol JF, et al:Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136:856-862, 2009.
PubMed
P.288 掲載の参考文献
1) 日本透析医学会統計調査委員会:図説 わが国の慢性透析療法の現況2008年12月31日現在. 2008年死亡患者の死亡原因分類19, 2009.
 
2) Fabrizi F, et al:The impact of hepatitis C virus infection on survival in dialysis patients:meta-analysis of observational studies. J Viral Hepat 14(10):697-703, 2007.
PubMed
3) The current state of chronic dialysis treatment in Japan (as of December 31, 2000). Ther Apher Dial 7(1):3-35, 2003.
PubMed
4) Asahina Y, et al:Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52(2):518-527, 2010.
PubMed
5) 透析医療における標準的な透析操作と院内感染予防に関するマニュアル:厚生科学特別研究事業「透析における感染症の実態把握と予防対策に関する研究班」平成11年度報告書.
 
6) 田中榮司:HCV感染の診断と検査 HCVコア抗原定量とHCVセログループ その利用法. 臨床医 28:47-49, 2002.
 
7) 伊藤敬義, 井廻道夫:HCVコア蛋白質. 検査と技術 34(11):1268-1270, 2006.
 
8) Fabrizi F, et al:Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 38:1009-1015, 2001.
PubMed
9) 菊地勘ほか:透析患者におけるHCV感染. 肝胆膵 43(5):747-753, 2001.
Medical*Online
10) Lopes EP, et al:Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol 35(3):298-302, 2006.
PubMed
11) Meyer CM, et al:Hepatitis C and renal disease:an update. Am J Kidney Dis 42(4):631-657, 2003.
 
12) Theodore D, et al:Liver biopsy in patients with inherited disorders of coagulation and chronic hepa-titis C. Haemophilia 10:413-421, 2004.
 
13) 田中寛人ほか:透析患者におけるC型慢性肝炎. 日本臨牀 62(増刊号7):645-648, 2004.
Medical*Online
14) Castera L, et al:Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 50:423-425, 2009.
 
15) Fujiyama S, et al:Hepatitis C:epidemiology and therapy-with special reference to long-term prognosis after IFN therapy. 臨床病理 48:5-13, 2000.
 
16) Evon DM, et al:Psychiatric symptoms during interferon treatment for hepatitis C:experiences from atertiary care hepatology centre. Aliment Pharmacol Ther 27(11):1071-1080, 2008.
 
17) Schafer A, et al:Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C-a critical review. Int J Methods Psychiatr Res 16:186-201, 2007.
PubMed
18) Majer M, et al:IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun 22:870-880, 2008.
PubMed
19) Martin-Santos R, et al:De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 27:257 -265, 2008.
 
20) Lang CA, et al:Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage 31(4):335-344, 2006.
PubMed
21) Ghany MG, et al:Diagnosis, management, and treatment of hepatitis C:an update. Hepatology 49(4):1335-1374, 2009.
PubMed
22) Peck RM, et al:Low-dose peginterferon alpha-2a(40Kd)(Pegasys(R)) to hepatitis C-infected, endstage renal disease patients undergoing haemodialysis:Final study results. 43rd Annual Meeting of the European Association for the Study of the Liver, Late-breakers, Milan, Italy, 2008.
 
23) Kidney Disease:Improving Global Outcomes(KDIGO):KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 109:S1-99, 2008.
PubMed
24) 今村道雄:HCV・HBV感染症. 日本臨牀 64(7):1310-1313, 2006.
Medical*Online
25) Festi D, et al:Safety of interferonβ treatment for chronic HCV hepatitis. World J Gastroenterol 10:12-16, 2004.
 
26) 荒瀬康司ほか:IFN療法の副反応とその対策. 日本臨牀 62(増刊号7):519-522, 2004.
Medical*Online
27) Pellicano R, et al:Interferon beta-1a alone or in combination with ribavirin:a randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 11:4484-4489, 2005.
PubMed
28) Zeniya M, et al:Significance of interferon-β for the treatment of hepatitis C virus infection in hemodialyzed patients. Hepatol Res 40:862-869, 2010.
 
29) Weclawiack H, et al:Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant 23:1043-1047, 2008.
PubMed
30) Mahmoud IM, et al:Interferon therapy in hemodialysis patients with chronic hepatitis C:study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 100:c133-c139, 2005.
PubMed
31) Hezode C, et al:Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360:1839-1850, 2009.
 
P.294 掲載の参考文献
1) 小池和彦:HIV感染症に合併する各種疾病に関する研究.厚生労働科学研究費補助金エイズ対策研究事業 平成19年度総括・分担研究報告書.
 
2) Koike K, et al:Prevalence of coinfection with human immunodeficiency virus and hepatitis C virus in Japan. Hepatol Res 37:2-5, 2007.
PubMed
3) Tatsunami S, et al:Current status of Japanese HIV-infected patients with coagulation disorders:coinfection with both HIV and HCV. Int J Hematol 88:304-310, 2008.
PubMed
4) Micallef JM, et al:Spontaneous viral clearance following acute hepatitis C infection:a systematic review of longitudinal studies. J Viral Hepat 13:34-41, 2006.
PubMed
5) Danta M, et al:Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 197:1558-1566, 2008.
PubMed
6) Dionne-Odom J, et al:Acute hepatitis C and HIV coinfection. Lancet Infect Dis 9:775-783, 2009.
PubMed
7) Kim AY, et al:Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med 3:e492, 2006.
PubMed
8) Thein HH, et al:Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection:a meta-analysis and meta-regression. Hepatology 48:418-431, 2008.
PubMed
9) Bica L et al:Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32:492-497, 2001.
 
10) HCV in HIV:Challenges and Opportunities. The PRN NOTEBOOK 6:14-18, 2001.(http://www.prn.org)
 
11) McGovern BH, et al:Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 43:365-372, 2006.
PubMed
12) Gaslightwala I, Bini EJ:Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 44:1026-1032, 2006.
PubMed
13) Kim AY, et al:The magnitude and breadth of hepatitis C virus-specific CD8+ Tcells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 105:1170-1178, 2005.
 
14) Brau N, et al:Presentation and outcome of hepatocellular carcinoma in HIV-infected patients:a U.S.-Canadian multicenter study. J Hepatol 47:527-537, 2007.
 
15) Puoti L, et al:Liver biopsy in hepatitis C virus carriers with normal alanine aminotransferase levels. Hepatology 50:655, 2009.
PubMed
16) Benhamou Y, et al:Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30:1054-1058, 1999.
 
17) Sulkowski MS, et al:Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 21:2209-2216, 2007.
PubMed
18) Martinez-Sierra C, et al:Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 36:491-498, 2003.
PubMed
19) Thein HH, et al:Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy:a meta-analysis. AIDS 22:1979-1991, 2008.
PubMed
20) Picchio GR, et al:Hepatitis C(HCV)genotype and viral titer distribution among Argentinean hemo-philic patients in the presence or absence of human immunodeficiency virus(HIV) co-infection, J Med Virol 52:219-225, 1997.
PubMed
21) Monga HK, et al:Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33:240-247, 2001.
PubMed
22) Yoo TW, et al:Hemophilia Growth and Development Study:Effect of hepatitis C virus(HCV) geno-type on HCV and HIV-1 disease. J Infect Dis 191:4-10, 2005.
 
23) Daar ES, et al;Hemophilia Growth and Development Study:Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 183:589-595, 2001.
PubMed
24) Tedaldi EM, et al;HIV Outpatient Study(HOPS) Investigators:Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 36:363-367, 2003.
PubMed
25) Cacoub P, et al:Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 32:1207-1214, 2001.
 
26) Haydon GH, et al:The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol 10:485-489, 1998.
PubMed
27) Sulkowski MS, et al:Hepatitis C and progression of HIV disease. JAMA 288:199-206, 2002.
PubMed
28) Rockstroh JK, et al;EuroSIDA Study Group:Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192:992-1002, 2005.
 
29) Al-Mohri H, et al:Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 44:463-469, 2007.
 
30) Macias J, et al:Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 55:409-414, 2006.
PubMed
31) Sanchez-Conde M, et al:Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 17(4):280-286, 2010.
PubMed
32) Okanoue T, et al:Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res 38:27-36, 2008.
PubMed
33) Maida I, et al:Liver fibrosis stage and HCV genotype distribution in HIV-HCV co-infected patients with persistently normal transaminases. AIDS Res Hum Retroviruses 23:801-804, 2007.
PubMed
34) Uberti-Foppa C, et al:Liver fibrosis in HIV-positive patients with hepatitis C virus:role of persistently normal alanine aminotransferase levels. J Acquir Immune Defic Syndr 41:63-67, 2006.
 
35) Perez-Olmeda M, et al:Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS 14:212, 2000.
PubMed
36) Asmuth DM, et al;Viral Activation Transfusion Study(VATS)Group:Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy(HAART) in patients with advanced HIV infection. Antiviral Res 63:123-131, 2004.
 
37) Kottilil S, et al:Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. HIV Clin Trials 5:25-32, 2004.
PubMed
38) Chung RT, et al;AIDS Clinical Trials Group 383 Study Team:Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 16:1915-1923, 2002.
 
39) Benhamou Y, et al:Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients:impact of protease inhibitor therapy. Hepatology 34:283-287, 2001.
PubMed
40) Kramer JR, et al:The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 100:56-63, 2005.
PubMed
41) Brau N, et al:Slower fibrosis progression in HIV/HCV-coinfected patients with successfuI HIV suppression using antiretroviral therapy. J Hepatol 44:47-55, 2006.
 
42) Qurishi N, et al:Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362:1708-1713, 2003.
 
43) Ragni MV, et al:Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 15(2):552-558, 2009.
PubMed
44) Mehta SH, et al:The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41:123-131, 2005.
 
45) Sulkowski MS, et al:Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283:74-80, 2000.
 
46) Montaner JS, et al:Antiretroviral treatment in 1998. Lancet 352:1919-1922, 1998.
PubMed
47) Martinez E, Gatell J:Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet 352:821-822, 1998.
PubMed
48) Bonacini M:Liver injury during highly active antiretroviral therapy:the effect of hepatitis C co-infection. Clin Infect Dis 38(Suppl 2):S104-S108, 2004.
PubMed
49) Atranzabal L, et al:Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 40:588-593, 2005.
 
50) Avidan NU, et al:Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr 52(4):452-458, 2009.
 
51) Sacchi A, et al:The basal activation state of DC subsets correlates with anti-HCV treatment out-come in HCV/HIV co-infected patients. Clin Immunol 138:178-186, 2011.
 
52) Vargas A, et al:Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1. J Acquir Immune Defic Syndr 54:219-220, 2010.
PubMed
53) Pineda JA, et al:Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 51:788-795, 2010.
PubMed
54) Aparicio E, et al:IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 5:e13771, 2010.
 
P.301 掲載の参考文献
1) 日本肝移植研究会:肝移植症例登録報告. 移植 44:559-571, 2009.
Medical*Online
2) Watt K, et al:A practical guide to the management of HCV infection following liver transplantation.Am J Transplant 9:1707-1713, 2009.
 
3) Gordon FD, et al:Treatment of hepatitis C in liver transplant recipients. Liver Transpl 15:126-135, 2009.
PubMed
4) Terrault NA:Hepatitis C therapy before and after liver transplantation. Liver Transpl 14(Suppl 2):S58-66, 2008.
PubMed
5) Schluger LK, et al:Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 23:971-976, 1996.
PubMed
6) Ueda Y, et al:Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation. J Viral Hepat 17:481-487, 2010.
PubMed
7) Berenguer M:Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 49:274-287, 2008.
PubMed
8) Ueda Y, et al:Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation. Transplantation 85:855-862, 2008.
PubMed
9) Ueda Y, et al:Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 90:661-665, 2010.
PubMed
10) Ueda Y, et al:Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation. J Viral Hepat. (in press).
 
11) 羽賀博典:肝移植拒絶反応における胆管上皮細胞障害. 肝胆膵 55:505-511, 2007.
Medical*Online
12) Stanca CM, et al:Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 84:180-186, 2007.
PubMed
13) Fernandez I, et al:Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C. Liver Transpl 15:948-955, 2009.
PubMed
14) Berardi S, et al:High incidence of allograft dysfunction in Iiver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence:possible de novo autoimmune hepatitis? Gut 56:237-242, 2007.
 
15) Watashi K, et al:Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282-1288, 2003.
PubMed
P.308 掲載の参考文献
1) Zignego AL, et al:Extrahepatic manifestations of Hepatitis C Virus infection:a general overview and guidelines for a clinical approach. Dig Liver Dis 39:2-17, 2007.
PubMed
2) Machida K, et al:Hepatitis C virus induces a mutator phenotype:enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 101:4262-4267, 2004.
PubMed
3) Machida K, et al:Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol 79:8079-8089, 2005.
 
4) Inokuchi M, et al:Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol 81:619-627, 2009.
PubMed
5) Ivanovski M, et al:Somatic hypermutation, clonal diversity, and preferential expression of the VH51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 91:2433-2442, 1998.
PubMed
6) Aalto SM, et al:Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 56:186-191, 1998.
PubMed
7) Flamand L, et al:Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol 67:6768-6777, 1993.
PubMed
8) Shimozuma Y, et al:Reactivation of Epstein-Barr virus in B cells of patients with chronic hepatitis C. J Med Virol 82:2064-2072, 2010.
 
9) Kawamura Y, et al:Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 120:1034-1041, 2007.
PubMed
10) Radkowski M, et al:Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 41:106-114, 2005.
PubMed
11) Pham TN, et al:Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78:5867-5874, 2004.
 
12) Nagao Y, et al:High prevalence of hepatitis C virus antibody and RNA in patients with oral cancer. J Oral Pathol Med 24:354-360, 1995.
PubMed
13) Koike K, et al:Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA 94:233-236, 1997.
PubMed
14) Tran A, et al:High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 18:253-257, 1993.
 
P.313 掲載の参考文献
1) 厚生労働省老健局老人保健課報告. [http://www.mhlw.go.jp/houdou/2007/10/h1003-1.html]
 
2) 日本赤十字社中央血液センター報告.
 
3) Tanaka Y, et al:A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 99:15584-15589, 2002.
PubMed
4) Tanaka Y, et al:Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatol 42:47-53, 2005.
PubMed
5) Yoshizawa H:Hepatocellular carcinoma associated with hepatitis C virus infection in Japan:projection to other countries in the foreseeable future. Oncology 62:8-17, 2002.
PubMed
6) 厚生労働省大臣官房統計情報部「人口動態統計」. [http://ganjoho.ncc.go.jp/professional/statistics/statistics.html]
 
7) Yoshida H, et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999.
PubMed
8) Lok AS, et al:Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136:138-148, 2009.
PubMed
9) Yoshida H, et al:Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 53:425-430, 2004.
PubMed
P.318 掲載の参考文献
1) Shiffman ML, et al:A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117:1164-1172, 1999.
PubMed
2) Ikeda K, et al:Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis:a prospective observation of 2215 patients. J Hepatol 28:930-938, 1998.
PubMed
3) Yoshida H, et al:Interferon therapy reduces the risk for hepatocellular carcinoma:national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999.
PubMed
4) Imai Y, et al:Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 129:94-99, 1998.
PubMed
5) Kasahara A, et al:Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27:1394-1402, 1998.
PubMed
6) Camma C, et al:Interferon and prevention of hepatocellular carcinoma in viral cirrhosis:an evidence-based approach. J Hepatol 34:593-602, 2001.
PubMed
7) Singal AK, et al:Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 8:192-199, 2010.
PubMed
P.324 掲載の参考文献
1) Shiratori Y, et al:Antiviral therapy for cirrhotic hepatitis C:association with reduced hepatocellular carclnoma development and improved survival. Ann Intern Med 142:105-114, 2005.
 
2) Mazzaferro V, et al:Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44:1543-1554, 2006.
PubMed
3) Suou T, et al:Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C;a pilot study. Hepatol Res 20:301-311, 2001.
PubMed
4) Shiratori Y, et al:Interferon therapy after tumor ablation improves prognosis in patients with hepato-cellular carcinoma associated with hepatitis C virus. Ann Intern Med 138:299-306, 2003.
 
5) Nishiguchi S, et al:Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 48:71-75, 2005.
 
6) Kudo M, et al:Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 72(Suppl 1):132-138, 2007.
 
7) Jeong SC, et al:Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 13:5343-5350, 2007.
PubMed
8) Miyake Y, et al:Meta-analysis:interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepatitis 17:287-292, 2010.
PubMed
9) Kubo S, et al:Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134:963-967, 2001.
 
10) Kubo S, et al:Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89:418-422, 2002.
PubMed
11) Lin SM, et al:Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 100:376-382, 2004.
PubMed
12) Sun HC, et al:Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma:a randomized clinical trial. J Cancer Res Clin Oncol 132:458-465, 2006.
PubMed
13) Lo CM, et al:A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245:831-842, 2007.
PubMed
14) Zhang CH, et al:Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma:a meta-analysis of randomized controlled trials. Int J Cancer 124:2982-2988, 2009.
PubMed
15) Ikeda K, et al:Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-232, 2000.
PubMed
16) Hung CH, et al:Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 20:1553-1559, 2005.
PubMed
17) Sakaguchi Y, et al:Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus- related hepatocellular carcinoma. Intervirology 48:64-70, 2005.
PubMed
18) Singal AK, et al:Meta-analysis:interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 32:851-858, 2010.
PubMed
19) Someya T, et al:Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma:a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 41:1206-1213, 2006.
PubMed
20) Kudo M:Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 75(Suppl 1):30-41, 2008.
PubMed

III B型肝炎

P.333 掲載の参考文献
1) 厚生労働省大臣官房統計情報部:平成20年人口動態統計, 上巻, 2008.
 
2) 三浦宣彦:肝がん死亡の地理的分布.平成21年度厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業 肝炎状況・長期予後の疫学に関する研究報告書, p41-153, 2010.
 
3) 日本肝癌研究会:第5回-第18回全国原発性肝癌追跡調査報告, 日本肝癌研究会事務局, 1982-2009.
 
4) 田中純子ほか:初回供血者集団(1995-2000年献血群, 2001-2006年献血群)を対象とした解析.肝炎ウイルス検診受診者(2002.4-2007.3受診群)を対象とした解析. 平成19年度厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業 肝炎状況・長期予後の疫学に関する研究報告書, p1-9, 2008.
 
5) Tanaka J, et al:Total Numbers of Undiagnosed Carriers of Hepatitis C and B Viruses in Japan Estimated by Age- and Area-specic Prevalence on the National Scale. Intervirology, 2011. (in press)
 
6) Koyama T, et al:Perinatal hepatitis B Virus infection in Japan. In:Congenital and Other Related Infectious Diseases of the Newborn, p141-151, Elsevier Science, Oxford, 2007.
 
7) Murokawa H, et al:Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testing. Vox Sang 88(1):10-16, 2005.
PubMed
8) 柚木久雄:核酸増幅検査(NAT)により見出されたHBV DNA陽性献血者の特性-795例の献血者の血清を対象とした分子ウイルス学的解析-. 厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業 平成19年度肝炎状況・長期予後の疫学に関する研究分担研究報告書, p59-62, 2008.
 
9) Yoshikawa A, et al:Age-and gender-specific distributions of hepatitis B virus(HBV) genotypes in Japanese HBV-positive blood donors. Transfusion 49(7):1314-1320, 2009.
PubMed
10) Kobayashi M, et al:Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol 37:35-39, 2002.
 
11) Hayashi K et al:Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. J Med Virol 79:366-373, 2007.
PubMed
12) World Health Organization Department of Communicable Diseases Surveillance and Response:Hepatitis B(WHO/CDS/CSR/LYO/2002.2:Hepatitis B). World Health Organization, Geneva, 2002. (http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html)
 
13) Media Centre:Hepatitis B(Fact sheet No204 Revised August 2008). World Health Organization, Geneva, 2008.(http://www.who.int/mediacentre/factsheets/fs204/en/index.html)
 
P.338 掲載の参考文献
1) Ozasa A, et al:Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 44:326-334, 2006.
PubMed
2) Omata M, et al:Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 324:1699-1704, 1991.
PubMed
3) Lok AS, McMahon BJ:Chronic hepatitis B:update 2009. Hepatology 50:661-662, 2009.
PubMed
4) European Association For The Study Of The Liver:EASL Clinical Practice Guidelines:management of chronic hepatitis B. J Hepatol 50:227-242, 2009.
 
5) Liaw YF, Chu CM:Hepatitis B virus infection. Lancet 373:582-592, 2009.
PubMed
6) Orito E, et al:Geographic distribution of hepatitis B virus(HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594, 2001.
PubMed
7) Enomoto M, et al:Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab 52:43-47, 2006.
PubMed
8) Chu CM, Liaw YF:HBsAg seroclearance in asymptomatic carriers of high endemic areas:appreciably high rates during a long-term follow-up. Hepatology 45:1187-1192, 2007.
PubMed
9) Loomba R, et al:Systematic review:the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-528, 2008.
PubMed
10) Umemura T, et al:Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52 -56, 2008.
 
11) Iloeje UH, et al;Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV(the REVEAL-HBV) Study Group:Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678-686, 2006.
 
12) Chen CJ, et al:Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73, 2006.
PubMed
P.343 掲載の参考文献
1) Blumberg BS, et al:A "new" antigen in leukemia sera. JAMA 191:541-546, 1965.
PubMed
2) Noguchi C, et al:Dual effect of APOBEC3G on Hepatitis B virus. J Gen Virol 88(Pt 2):432-440, 2007.
PubMed
3) Kim CM, et al:HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351(6324):317-320, 1991.
PubMed
4) Koike K, et al:High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19(4):810-819, 1994.
 
5) Tateno C, et al:Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165(3):901-912, 2004.
PubMed
6) Tsuge M, et al:Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42(5):1046-1054, 2005.
PubMed
7) Orito E, et al:Geographic distribution of hepatitis B virus(HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34(3):590-594, 2001.
PubMed
8) Yang HI, et al;REVEAL-HBV Study Group:Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100(16):1134-1143, 2008.
 
9) Liu S, et al:Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma:a meta-analysis. J Natl Cancer Inst 101(15):1066-1082, 2009.
PubMed
10) Yotsuyanagi H, et al:Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol 77:39-46, 2005.
PubMed
11) Arima S, et al:Impaired function of antigen-presenting dendritic cells in patients with chronic hepatitis B:localization of HBV DNA and HBV RNA in blood DC by in situ hybridization. Int J Mol Med 11(2):169-174, 2003.
PubMed
12) Kamatani Y, et al:A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41(5):591-595, 2009.
PubMed
13) Zhou J, et al:Functional dissection of an IFN-alpha/beta receptor 1 promoter variant that confers higher risk to chronic hepatitis B virus infection. J Hepatol 51(2):322-332, 2009.
 
14) Kim HS, et al:Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B. Gastroenterology 136(2):505-512, 2009.
PubMed
15) Wu JF, et al:Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology 138(1):165-172, 2010.
PubMed
P.349 掲載の参考文献
1) Blumberg BS, et al:A "new" antigen in leukemia sera. J Am Med Assoc 191:541-546, 1965.
 
2) Okochi K, Murakami S:Observation on Australia antigen in Japanese. Vbx Sang 15:374-385, 1968.
 
3) Dane DS, et al:Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1:695-698, 1970.
 
4) Galibert F, et al:Nucleotide sequence of the hepatitis B virus genome(subtype ayw) cloned in E. coli. Nature 281:646-650, 1979.
 
5) Arauz-Ruiz P, et al:Genotype H:a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 83:2059-2073, 2002.
 
6) Seeger C, et al:Hepadnaviruses. In:Fields Virology(ed by Knipe DM, Howley PM), p2977-3029, Lippincott Williams & Wilkins, Pennsylvania, 2007.
 
7) Utsumi T, et al:Complete genome sequence and phylogenetic relatedness of hepatitis B virus iso-lates in Papua, Indonesia. J Clin Microbiol 47:1842-1847, 2009.
 
8) Fung SK Lok AS:Hepatitis B virus genotypes:do they play a role in the outcome of HBV infection? Hepatology 40:790-792, 2004.
PubMed
9) Suzuki F, et al:Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 37:824-830, 2002.
PubMed
10) Huo TI, et al:Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 20:3620-3628, 2001.
PubMed
11) Hirsch RC, et al:Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription. Nature 344:552-555, 1990.
 
12) Zhang YY, et al:Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavi-rusinfected liver. Proc Natl Acad Sci USA 100:12372-12377, 2003.
 
13) Wong DK, et al:Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 40:727-737, 2004.
PubMed
14) Wong DK, et al:Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol 45:553-559, 2006.
PubMed
15) Yang W, Summers J:Integration of hepadnavirus DNA in infected liver:evidence for a linear precursor. J Virol 73:9710-9717, 1999.
PubMed
P.355 掲載の参考文献
1) Kato H, et al:Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. World J Gastroenterol 11:6295-6304, 2005.
PubMed
2) Miyakawa Y, Mizokami M:Classifying hepatitis B Virus genotypes. Intervirology 46:329-338, 2003.
PubMed
3) Tanaka Y, et al:A case-control study for differences among hepatitis B virus infections of geno-types A(subtypes Aa and Ae) and D. Hepatology 40:747-755, 2004.
 
4) Matsuura K, et al:Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 47:1476-1483, 2009.
 
5) Orito E, et al:Geographic distribution of hepatitis B virus(HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594, 2001.
PubMed
6) Orito E, et al:A case-control study for clinical and molecular biological differences betWeen hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33:218-223, 2001.
 
7) Ozasa A, et al:Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 44:326-334, 2006.
PubMed
8) Sugauchi F, et al:Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 76:5985-5992, 2002.
 
9) Sugauchi F, et al:Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 124:925-932, 2003.
PubMed
10) Sakamoto T, et al:Novel subtypes(subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. J Gen Virol 87:1873-1882, 2006.
 
11) Tanaka Y, et al:Spechic mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 45:646-653, 2006.
PubMed
12) Wang Z, et al:Clinical and Virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J Clin Microbiol 45:1491-1496, 2007.
 
13) Kao JH, et al:Hepatitis B genotypes and the response to interferon therapy. J Hepatol 33:998-1002, 2000.
PubMed
14) Kao JH, Chen DS:Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. Gastroenterology 125:1916-1917;author reply 1917-1918, 2003.
 
15) Erhardt A, et al:Mutations of the core promoter and response to interferon treatment in chronic rep-licative hepatitis B. Hepatology 31:716-725, 2000.
 
16) Sendi H, et al:T1764G1766 core promoter double mutants are restricted to Hepatitis B virus strains with an A1757 and are common in genotype D. J Gen Virol 86:2451-2458, 2005.
 
17) Elkady A, et al:Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. J Gastroenterol Hepatol 23:474-481, 2008.
PubMed
18) Erhardt A, et al:Response to antiviral treatment in patients infected With hepatitis B virus genotypes E-H. J Med Virol 81:1716-1720, 2009.
 
19) Sanchez-Tapias JM, et al:Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 123:1848-1856, 2002.
 
20) Livingston SE, et al:Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma:preponderance of genotype F. J Infect Dis 195:5-11, 2007.
 
21) Tatematsu K, et al:A genetic variant of hepatitis B Virus divergent from known human and ape geno-types isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 83:10538-10547, 2009.
 
P.362 掲載の参考文献
1) Yamashita T, et al:Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem Biophys Res Commun 282:647-654, 2001.
PubMed
2) Yamashita T, et al:Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol 50:100-110, 2009.
PubMed
3) Honda M, et al:Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 120:955-966, 2001.
 
4) Honda M, et al:Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 44:1122-1138, 2006.
PubMed
P.368 掲載の参考文献
1) Baumert TF, et al:Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. Hepatology 41:247-256, 2005.
PubMed
2) Korba BE, et al:Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther 9:937-952, 2004.
PubMed
3) Chisari FV, et al:Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 84:6909-6913, 1987.
PubMed
4) Koike K, et al:High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19:810-819, 1994.
 
5) Araki K, et al:Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci USA 86:207-211, 1989.
PubMed
6) Guidotti LG, et al:High-level hepatitis B virus replication in transgenic mice. J Virol 69:6158-6169, 1995.
PubMed
7) Guidotti LG, et al:Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829, 1999.
PubMed
8) Onji M, Akbar SMF:Consequences of interactions between DC and virus. In:Dendritic Cells in Clinics(ed by Onji M, et al), p49-66, Springer, Tokyo, 2008.
 
9) Akbar SMF, et al:Immune modulator and antiviral potential of dendritic cells pulsed With both hepatitis B surface antigen and core antigen for treating chronic HBV infection. Antivir Ther 15:887-895, 2010.
 
10) Isogawa M, et al:Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology 333:293-300, 2005.
PubMed
11) Yang PL, et al:Hydrodynamic injection of viral DNA:a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 99:13825-13830, 2002.
PubMed
12) Ilan E, et al:The hepatitis B virus-trimera mouse:a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 29:553-562, 1999.
 
13) Brown JJ, et al:A long-term hepatitis B viremia model generated by transplanting non-tumorigenic immortalized human hepatocytes in Rag-2-deficient mice. Hepatology 31:173-181, 2000.
 
14) Sandgren EP, et al:Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 66:245-256, 1991.
PubMed
15) Tsuge M, et al:Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42:1046-1054, 2005.
PubMed
P.372 掲載の参考文献
1) 恩地森一:B型肝炎ウイルス感染症. 肝疾患と肝免疫, p39-50, 中外医学社, 2008.
 
2) Bertoletti A, Gehring AJ:The immune response during hepatitis B virus infection. J Gen Virol 87:1439-1449, 2006.
PubMed
3) Wieland S, et al:Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101:6669-6674, 2004.
PubMed
4) Webster GJ, et al:Incubation phase of acute hepatitis B in man:dynamic of cellular immune mechanisms. Hepatology 32:1117-1124, 2000.
PubMed
5) Dunn C, et al:Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137:1289-1300, 2009.
PubMed
6) Wu J, et al:Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49:1132-1140, 2009.
PubMed
7) Guy CS, et al:Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol 82:8579-8591, 2008.
PubMed
8) Fisicaro P, et al:Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58:974-982, 2009.
PubMed
9) Hosel M, et al:Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50:1773-1782, 2009.
 
10) Onji M, Akbar SMF:Dendritic Cells in Clinics, 2nd ed, Springer, Tokyo, 2008.
 
11) Thimme R, et al:CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B Virus infection. J Virol 77:68-76, 2003.
PubMed
12) Rehermann B, et al:The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108, 1996.
PubMed
13) Urbani S, et al:Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 41:826-831, 2005.
PubMed
14) Zhang Z, et al:Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134:1938-1949, 2008.
PubMed
15) Xu D, et al:Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177:739-747, 2006.
PubMed
P.377 掲載の参考文献
1) Wieland S, et al:Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101:6669-6674, 2004.
PubMed
2) Fisicaro P, et al:Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58:974-982, 2009.
PubMed
3) Thimme R, et al:CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77:68-76, 2003.
PubMed
4) Asabe S, et al:The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 83:9652-9662, 2009.
 
5) Guidotti LG, et al:Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829, 1999.
PubMed
6) Webster GJ, et al:Incubation phase of acute hepatitis B in man:dynamic of cellular immune mechanisms. Hepatology 32:1117-1124, 2000.
PubMed
7) Maini MK, et al:Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 117:1386-1396, 1999.
 
8) Nakamura I, et al:Pathogenesis of experimental neonatal woodchuck hepatitis virus infection:chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 33:439-447, 2001.
PubMed
9) Wang Y, et al:Role of type 1 versus type 2 immune responses in liver during the onset of chronic woodchuck hepatitis virus infection. Hepatology 37:771-780, 2003.
PubMed
10) Szkaradkiewicz A, et al:HBcAg-specific cytokine production by CD4 T lymphocytes of children with acute and chronic hepatitis B. Virus Res 97:127-133, 2003.
PubMed
11) Rehermann B, et al:Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 70:7092-7102, 1996.
 
12) Boni C, et al:Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968-975, 1998.
PubMed
13) Rehermann B, et al:Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97:1655-1665, 1996.
PubMed
14) Kondo Y, et al:Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity. J Med Virol 74:425-433, 2004.
PubMed
15) Beckebaum S, et al:Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro:mechanisms for viral immune escape. Immunology 109:487-495, 2003.
PubMed
16) Kondo Y, et al:Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes. J Infect Dis 2021202-213, 2010.
 
17) Fisicaro P, et al:Antiviral intrahepatic T-cell response can be restored by blocking programmed death-1 pathway in chronic hepatits B. Gastroenterology 138:682-693, 2010.
 
18) Ben-Ari Z, et al:Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 98:144-150, 2003.
PubMed
19) Kim YJ, et al:Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 12:2541-2546, 2003.
PubMed
20) Kamatani I, et al:A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41:591-595, 2009.
PubMed
21) Ozawa A, et al:Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus Infection. Hepatology 44:326-334, 2006.
PubMed
22) Sugiyama M, et al:Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 44:915-924, 2006.
PubMed
23) Sugiyama M, et al:Basic-liver, pancreas, and biliary tract. Gastroenterology 136:652-662, 2009.
 
P.382 掲載の参考文献
1) Chu CM, Liaw YF:Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 15:133-143, 2010.
PubMed
2) Chu MC, Liaw YF:HBsAg seroclearance in asymptomatic carriers of high endemic area:Appreciably high rates during a long-term follow-up. Hepatology 45:1187 -1192, 2007.
 
3) Fattovich G, et al:Long-term outcome of chronic hepatitis B in Caucasian patients:mortality after 25years. Gut 57:84-90, 2008.
 
4) Manno M, et al:Natural history of chronic HBV carriers in Northern Italy:Morbidity and mortality after 30 years. Gastroenterology 127:756-763, 2004.
PubMed
5) Yuen MF, et al:HBsAg seroclearance in chronic hepatitis B in the Chinese:virological, histological, and clinical aspects. Hepatology 39:1694-1701, 2004.
PubMed
6) Ahn SH, et al:Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance, J Hepatol 42:188-194, 2005.
PubMed
7) Arase Y, et al:Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 119:e9-e15, 2006.
PubMed
8) Liaw YF, et al:Incidence, determinants, and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection:A prospective study. Hepatology 13:627-631, 1991.
PubMed
9) McMahon BJ, et al:Serologic and clonical outcomes 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 8:759-768, 2001.
 
10) Simonetti J, et al:Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51:1531-1537, 2010.
 
11) Furusyo N, et al:Hepatitis B surface antigen disappearance and hepatitis B suface antigen subtype:a prospective, long-term, follow-up study of Japanese residents of Okinawa Japan with chronic hepatitis B infection. Am J Trop Med Hyg 60:616-622, 1999.
 
12) Huo TI, et al:Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 28:231-236, 1998.
 
13) Chen YC, et al:Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 123:1084-1089, 2002.
PubMed
14) Ohkoshi S, et al:Remote development of hepatocellular carcinoma in patients with liver cirrhosis type B serologically cured for HBs antigenemia with long-standing normalization of ALT values. Dig Dis Sci 47:2002-2006, 2002.
 
15) Yuen MF, et al:HBsAg seroclearance in chronic hepatitis B in Asian patients:replicative level and risk of hepatocellular carcinoma. Gastroenterology 135:1192-1199, 2008.
PubMed
16) Tong MJ, et al:Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 7:889-893, 2009.
PubMed
17) Allain JP:Occult hepatitis B virus infection. Transfus Clin Biol 11:18-25, 2004.
PubMed
18) Raimondo G, et al:Statements from the Taormina expert meeting on occult hepatitis B infection. J Hepatol 49:652-657, 2008.
PubMed
19) Moucari R, et al:High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon:a long-term follow-up study. J Hepatol 50:1084-1092, 2009.
PubMed
20) Lin SM, et al:Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46:45-52, 2007.
PubMed
21) Buster EH, et al:Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha 2b. Gastroenterology 135:459-467, 2008.
PubMed
22) Chisari FV, et al:Pathogenesis of hepatitis B virus infection. Pathol Biol(Paris) 58:258-266, 2010.
PubMed
23) Yotsuyanagi H, et al:Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 27:1377-1382, 1998.
PubMed
24) Chaar ME, et al:Impact of hepatitis B surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 52:1600-1610, 2010.
 
25) Ito K et al:Impairment of hepatitis B virus virion secretion by single amino acids substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol, 2010. [Epub ahead of print]
 
26) Zhang ZH, et al:Elimination of hepatitis B Virus surface antigen and appearance of neutralizing anti-bodies in chronically infected patients without viral clearance. J Viral Hepatitis, 2010. [Epub ahead of print]
 
27) Yuki N, et al:Long-term histological and virologic outcomes of acute self-limited hepatitis B. Hepatology 37:1172-1179, 2003.
 
P.388 掲載の参考文献
1) B型肝炎について- 一般的なQ&A改訂版, 厚生労働省, 2006.
 
2) 肝がん白書, 社団法人日本肝臓学会, 1999.
 
3) Suzuki F et al:Correlation between serum hepatitis B virus corerelated antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 81:27-33, 2009.
PubMed
4) Hosaka T, et al:HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 30:1461-1470, 2010.
PubMed
5) Miyakawa Y, Mizokami M:Classifying hepatitis B virus genotypes. Intervirology 46:329-338, 2003.
PubMed
6) Lindth M, et al:Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scale analysis using a new genotyping method. J Infect Dis 175:1285-1293, 1997.
 
7) Kao JH, et al:Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554-559, 2000.
PubMed
8) Kobayashi M, et al:Clinical characteristics of patients infected with hepatitis B virus genotype A, B and C. J Gastroenterol 37:35-39, 2002.
 
9) Suzuki Y, et al:Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 76:33-39, 2005.
PubMed
10) Erhardt A, et al:Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 31:716-725, 2000.
PubMed
11) Zollner B, et al:20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 357:934-935, 2001.
PubMed
12) Okamoto H, et al:Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 68:8102-8110, 1994.
 
13) BuckWold VE, et al:Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 70:5845-5851, 1996.
PubMed
P.395 掲載の参考文献
1) Chang MH, et al:Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336:1855-1859, 1997.
 
2) Chang MH:Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol Int 2(Suppl 1):28-36, 2008.
 
3) Rots NY, et al:Hepatitis B vaccination strategies tailored to different endemicity levels:some considerations. Vaccine 28:893-900, 2010.
PubMed
4) Lolekha S, et al:Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 20:3739-3743, 2002.
PubMed
5) Jonas MM:Hepatitis B and pregnancy:an underestimated issue. Liver Int 29(Suppl 1):133-139, 2009.
 
6) Buchanan C, Tran TT:Management of chronic hepatitis B in pregnancy. Clin Liver Dis 14:495-504, 2010.
PubMed
7) Ni YH, et al:Two decades of universal hepatitis B vaccination in taiwan:impact and implication for future strategies. Gastroenterology 132:1287-1293, 2007.
PubMed
8) Beasley RP:Rocks along the road to the control of HBV and HCC. Ann Epidemiol 19:231-234, 2009.
 
9) 小松陽樹ほか:国際方式によるB型肝炎母子感染予防効果の検討. 肝臓 51:92-94, 2010.
 
10) 乾あやのほか:B型肝炎母子感染防止不成功例の解析. 肝臓 51:457 -459, 2010.
 
11) Willis BC, et al:Gaps in hospital policies and practices to prevent perinatal transmission of hepatitis B virus. Pediatrics 125:704-711, 2010.
PubMed
12) Weinbaum CM, et al:Centers for Disease Control and Prevention(CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57(RR-8):1-20, 2008.
PubMed
13) Zuckerman J, et al:Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe? Lancet Infect Dis 7:410-419, 2007.
PubMed
14) Komatsu H, et al:Source of transmission in children with chronic hepatitis B infection after the implementation of a strategy for prevention in those at high risk. Hepatol Res 39:569-576, 2009.
PubMed
15) Aomatsu T, et al:Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier. Eur J Pediatr 169:167-171, 2010.
 
16) Komatsu H, et al:Does the spread of hepatitis B virus genotype A increase the risk of intrafamilial transmission in Japan? J Infect Chemother, 2010. (Epub ahead of print)
 
17) Richardson G, et al:Hepatitis B immunisation of household contacts:retrospective study of vaccine coverage. J Epidemiol Community Health 55:934-935, 2001.
PubMed
P.400 掲載の参考文献
1) Hayashi J, et al:Hepatitis B virus transmission in nursery schools. Am J Epidemiol 125:492-498, 1987.
PubMed
2) Omata M, et al:Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 324:1699-1704, 1991.
PubMed
3) Milich DR et al:The selected hepatitis B precore antigen can modulate the immune response to the nucleocapsid:a mechanism for persistence. J Immunol 160:2013-2021, 1998.
 
4) 林純, 古庄憲浩:肝炎ウイルスマーカー. 臨牀と研究 83:188-192, 2006.
Medical*Online
5) 林純ほか:ウイルス肝炎-HBs抗原消失の機序とその問題点. 日本臨牀 62:106-111, 2004.
 
6) Paez Jimenez A, et al:Community transmission of hepatitis B virus in Egypt:results from a case-control study in Greater Cairo. Int J Epidemiol 38:757-765, 2009.
PubMed
7) Ashraf H, et al:Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, Bangladesh. BMC Infect Dis 10:208-215, 2010.
 
8) Furusyo N, et al:Clinical outcomes of hepatitis B virus(HBV) genotypes B and C in Japanese patients with chronic HBV infection. Am J Trop Med Hyg 67:151-157, 2002.
 
9) 田中靖人, 溝上雅史:性感染症としてのB型肝炎ウイルス感染症. 臨床とウイルス 37:32-37, 2009.
Medical*Online
10) Coppola N, et al:Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. J Viral Hepat 17:493-500, 2010.
 
11) van Houdt R, et al:Ongoing transmission of a single hepatitis B virus strain among men having sex with men in Amsterdam. J Viral Hepat 17:108-114, 2010.
 
12) 澤山泰典ほか:Commercial sex workers(CSW)およびSTD患者におけるHCVおよびHBV感染と梅毒疾患. 日性感染症会誌 8:116-121, 1997.
 
13) Kubo N, et al:A patient in whom only hepatitis B virus(HBV) was thought to have been contracted, by kissing, from a same-sex partner coinfected with HBV and human immunodeficiency virus-1. J Infect Chemother 9:260-264, 2003.
PubMed
14) 林純ほか:医療従事者におけるHBワクチン接種後の長期観察. 感染症誌 62:805-810, 1988.
 
15) Szmuness W, et al:Hepatitis B vaccine;Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United Stages. N Engl J Med 303:833-841, 1980.
 
P.407 掲載の参考文献
1) 吉沢浩司, 飯野四郎:肝炎ウイルスについて. ウイルス肝炎 診断/予防/治療, 第2版p2-5, 文光堂, 2002.
 
2) 吉沢浩司, 飯野四郎:B型肝炎.ウイルス肝炎 診断/予防/治療, 第2版, p13-36, 文光堂, 2002.
 
3) 八橋弘:「厚生労働省科学研究補助金(肝炎等克服緊急対策研究事業). 国立病院機構共同臨床研究:本邦における急性肝炎の疫学調査および欧米型B型(genotype A)肝炎とE型肝炎の発生状況に関する研究」平成19年度報告書, p1-7, 2008.
 
4) Yotsuyanagi H, et al:Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol 77:39-46, 2005.
PubMed
5) Yotsuyanagi H, et al:Frequent presence of HBV in sera of HBsAg-negative, anti-HBc-positive blood donors. Transfusion 41:1093-1099, 2001.
PubMed
6) 山田典栄ほか:首都圏におけるB型急性肝炎の実態と変遷:-Genotype Aに焦点をあてて-. 肝臓 49:553-559, 2008.
 
7) Shreiber GB, et al:The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 334:1685-1690, 1996.
 
8) Uemoto S, et al:Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 65:494-499, 1998.
PubMed
9) 厚生労働省:「血液製剤の安全性の向上及び安全供給の確保を図るための基本的な方針」厚生労働省告示207号, 平成15年5月19日.
 
10) 厚生労働省:「血液製剤等に係る遡及調査ガイドライン」, 薬食発第0310012号医薬食品局長通知, 平成17年3月10日.
 
11) 清水勝:教育講座1 ウイルス肝炎の予防, p52, 国際出版, 1983.
 
12) 志方俊夫ほか:e抗原陽性及び陰性B型肝炎carrier血清の感染症に関する研究-チンパンジーによる感染実験-. 肝臓 18:388-394, 1977.
 
13) 慢性肝炎の治療ガイド2008. 日本肝臓学会(編), p21, 文光堂, 2008.
 
14) Nakano K, et al:Analysis of anti-HBs levels in healthcare workers over 10 years following booster vaccination for hepatitis B Virus. Vaccine 21:3789-3794, 2003.
 
15) 袖山健, 小林正和:医療機関内におけるHBV感染経路と予防対策-リスクマネージメントの立場から-. 日本臨牀 62(増刊号8):203-209, 2004.
Medical*Online
P.415 掲載の参考文献
1) 厚生労働 :B型肝炎について(一般的なQ&A) 平成20年4月改訂(改訂第3版), p1-42, 2008. (http://www.mhlw.go.jp)
 
2) Mast EE, et al:A comprehensive immunization strategy to eliminate transmission of hepatitis B Virus infection in the United States:recommendations of the Advisory Committee on Immunization Practice(ACIP) Part I:Immunization of infants, children, and adolescents. MMWR Recomm Rep 54(RR-16):1-31, 2005.
PubMed
3) Mast EE, et al:A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States:recommendations of the Advisory Committee on Immunization Practice(ACIP) Part II:immunization of adults. MMWR Recomm Rep 55(RR-16):1-33, 2006.
PubMed
4) Mast EE, Ward JW:Hepatitis B vaccines. In:Vaccines (ed by Plotkin SA, et al), 5th ed, p 205-241, Saunders Elsevier, New York, 2008.
 
5) World Health Organization:Progress towards global immunization goals-2009, Summary presentation of key indicators, Updated August 2010. p12-13, 2010.(http://www.who.int/)
 
6) 水落利明:ユニバーサルHBワクチン接種に関する提言. 厚生労働科学研究費補助金肝炎等克服緊急対策事業「肝炎ウイルス感染防御を目指したワクチン接種の基盤構築」平成19-21年度総合研究報告書(水落利明研究代表者), p194-224, 2010.
 
7) 溝上雅史, 四柳宏:ワークショップ「B型肝炎の母子および水平感染の実態とワクチン戦略」. 肝臓 51(Suppl 1):A69-A76, 2010.
 
8) 白木和夫:わが国におけるB型肝炎母子感染防止の経緯とuniversal vaccinationの必要性について. 小児感染免疫 21:149-157, 2009.
 
9) 小方則夫:B型肝炎ウイルス(hepatitis B virus:HBV)感染症対策:日本において接種可能である(あった)4種HBワクチンのHBs抗体誘導能の凝集法(passive hemagglutination assay)評価と国際単位表示法(chemiluminescent immunoassay)評価との比較検討.臨床病理(日本臨床検査医学会誌) 57:954-960, 2009.
 
10) 小方則夫:国際基準共有に向けたB型肝炎ウイルス感染防御HBs抗体評価標準化の必要性-本邦にて汎用されるHBs抗体測定法の特性乖離-. 臨床病理(日本臨床検査医学会誌) 54:960-965, 2006.
 
11) Ogata N, et al:Antibody to hepatitis B surface antigen(anti-HBs) induced by a recombinant hepatitis B vaccine consisting of subtype adr antigen is underestimated on the World Health Organization(WHO) -standardized assays. Intern Med 42:446-447, 2003.
 
12) 小方則夫:日本におけるUniversal HB vaccination実施に向けての課題:日本で使用されるHBワクチン性能とHBs抗体測定キット特性の検討, およびHBワクチン・エスケープとされるHBV変異株の霊長類モデル感染実験の概要. 厚生労働科学研究費補助金肝炎等克服緊急対策事業「肝炎ウイルス感染防御を目指したワクチン接種の基盤構築」平成19-21年度総合分担報告書(水落利明研究代表者), p35-47, 2010.
 
13) Ogata N, et al:Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci USA 90:3014-3018, 1993.
 
14) Hollinger FB, Dressman GR:Immunobiology of hepatitis viruses. In:Manual of Clinical Laboratory Immunology(ed by Rose NR, et al), 3rd ed, p558-572, American Society for Microbiology, Washington, DC, 1986.
 
15) Huzly D, et al:Comparison of nine commercially available assays for quantification of antibody response to hepatitis B surface antigen. J Clin Micobiol 46:1298-1306, 2008.
 
16) Carman WF, et al:Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-329, 1990.
PubMed
17) Ogata N, et al:Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 30:779-786, 1999.
PubMed
P.421 掲載の参考文献
1) Hoofnagle JH, et al:Management of hepatitis B:summary of a clinical research workshop. Hepatology 45:1056-1075, 2007.
PubMed
2) Lee WM:Hepatitis B virus infection. N Engl J Med 337(11):1733-1745, 1997.
 
3) Liang TJ:Hepatitis B:the virus and disease. Hepatology 49:S13-21, 2009.
PubMed
4) Tuttleman JS, et al:Formation of the pool of covalently closed circular viral DNA in hepadnavirusinfected cells. Cell 47:451-460, 1986.
PubMed
5) Arbuthnot P, et al:Putative role of hepatitis B virus X protein in hepatocarcinogenesis:effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol 15:357-368, 2000.
PubMed
6) Rehermann B, et al:The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108, 1996.
PubMed
7) Tanaka E, Umemura T:History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the World. Clin J Gastroenterol 1:83-86, 2008.
 
8) 田中榮司:B型肝炎再活性化の病態と対策 日消誌 107:1417-1425, 2010.
Medical*Online
9) Umemura T, et al:Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52-56, 2008.
PubMed
P.426 掲載の参考文献
1) Orito E, et al:Geographic distribution of hepatitis B virus(HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34(3):590-594, 2001.
PubMed
2) Ozasa A, et al:Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 44(2):326-334, 2006.
PubMed
3) Matsuura K, et al:Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 47(5):1476-1483, 2009.
 
4) Orito E, et al:A case-control study for clinical and molecular biological differences betWeen hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33(1):218-223, 2001.
 
5) Kao JH, et al:Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118(3):554-559, 2000.
PubMed
6) Sugauchi F, et al:Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol 76(12):5985-5992, 2002.
 
7) Sugauchi F, et al:Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 124(4):925-932, 2003.
PubMed
8) Kusakabe A, et al:Case-control study for the identification of virological factors associated with fulminant hepatitis B. Hepatol Res 39(7):648-656, 2009.
PubMed
9) Hayashi K, et al:Prevalence of hepatitis B virus subgenotypes and basal core promoter, precore variants in patients with acute hepatitis B in central Vietnam. Intervirology 52(1):22-28, 2009.
PubMed
10) Sakamoto T, et al:Classification of hepatitis B Virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. J Infect Dis 196(10):1487-1492, 2007.
PubMed
11) Xu Z, et al:Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease:an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol, 2010.[Epub ahead of print]
 
12) Sugiyama M, et al:Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 136(2):652-662 e3, 2009.
 
13) Yang HI, et al:Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100(16):1134-1143, 2008.
PubMed
14) Orito E, et al:Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan. Intervirology 48(4):239-245, 2005.
 
15) Shinkai N, et al:Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol 45(10):3191-3197, 2007.
PubMed
16) Yuen MF, et al:Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 57(1):98-102, 2008.
 
17) Kim JK, et al:Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. J Med Virol 81(6):1002-1008, 2009.
PubMed
18) Bai X, et al:Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high-risk for hepatocellular carcinoma. Carcinogenesis 32(1):63-68, 2011.
PubMed
19) Chisari FV, et al:Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59(6):1145-1156, 1989.
PubMed
20) Sugauchi E et al:Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 70(4):537-544, 2003.
 
21) Yotsuyanagi H, et al:Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol 77(1):39-46, 2005.
PubMed
22) Suzuki Y, et al:Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 76(1):33-39, 2005.
PubMed
23) Sugauchi F, et al:Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res 36(2):107-114, 2006.
PubMed
24) Sugauchi F, et al:Epidemiological and sequence differences between two subtypes(Ae and Aa) of hepatitis B virus genotype A. J Gen Virol 85(Pt 4):811-820, 2004.
 
25) Kramvis A, et al:Nucleic acid sequence analysis of the precore region of hepatitis B virus from sera of southern African black adult carriers of the virus. Hepatology 25(1):235-240, 1997.
PubMed
26) Niederau C, et al:Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334(22):1422-1427, 1996.
PubMed
27) Tanaka Y, et al:A case-control study for differences among hepatitis B virus infections of geno-types A(subtypes Aa and Ae) and D. Hepatology 40(3):747-755, 2004.
 
28) Ahn SH, et al:Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. Gastroenterology 125(5):1370-1378, 2003.
PubMed
29) Kramvis A, Kew MC:Structure and function of the encapsidation signal of hepadnaviridae. J Viral Hepat 5(6):357-367, 1998.
PubMed
30) Sanchez-Tapias JM, et al:Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 123(6):1848-1856, 2002.
 
31) Elkady A, et al:Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. J Gastroenterol Hepatol 23(3):474-481, 2008.
PubMed
32) Chandra PK, et al:Subgenotypes of hepatitis B virus genotype D(D1, D2, D3 and D5) in India:dif-ferential pattern of mutations, liver injury and occult HBV infection. J Viral Hepat 16(10):749-756, 2009.
 
P.433 掲載の参考文献
1) Chu CJ, et al:Prevalence of HBV precore/core promoter variants in the United States. Hepatology 38:619-628, 2003.
PubMed
2) Sumi H, et al:Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 37:19-26, 2003.
 
3) Chu CM, Liaw YF:Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 133:1458-1465, 2007.
PubMed
4) Wu S, et al:Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion. J Hepatol 54:19-25, 2011.
 
5) Wu S, et al:Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines. Viral Immunol 23:467-476, 2010.
PubMed
6) Voiz T, et al:Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 133:843-852, 2007.
 
P.438 掲載の参考文献
1) 吉澤浩司:わが国における肝炎ウイルス感染の実態と肝炎, 肝がん対策. 日臨内科医会誌 21:12-18, 2006.
Medical*Online
2) Okada K et al:eantigen and anti-e in serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 294:747-749, 1976.
 
3) Beasley RP, et al:The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 105:94-98, 1977.
 
4) 福田信臣ほか:乳幼児におけるHBウイルスcarrier成立年齢について. 肝臓 19:936-941, 1978.
 
5) Hoofnagle JH, et al:Management of hepatitis B:summary of a clinical research workshop. Hepatology 45:1056-1075, 2007.
PubMed
6) 八橋弘:B型肝炎-自然経過と感染予防. コンセンサス肝疾患2002 診断・治療と病態(矢野右人監), p63-70, 日本メディカルセンター, 2002.
 
7) Koyama T, et al:Prevention of perinatal hepatitis B virus transmission by combined passive-active immunoprophylaxis in Iwate, Japan (1981-1992) and epidemiological evidence its efficacy. Hepatol Res 26:287-292, 2003.
PubMed
8) Orito E, et al:A case-control study for clinical and molecular biological difference between B viruses of genotype B and C. Japan HBV Genotype Research Group. Hepatology 33:218-223, 2001.
 
9) 新妻宏史ほか:HBV genotype Aの急性感染からキャリア化した成人例の検討. 肝臓 40:346-349, 1999.
 
10) 菊池健太郎ほか:HBV genotype A初感染後キャリア化した夫より夫婦間感染した妻の急性B型肝炎の1例. 肝臓 39:533-538, 1998.
 
11) Tanaka J, et al:Sex-and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3, 485, 648 first-time blood donors during 1995-2000. Intervirology 47:32-40, 2004.
 
12) 折戸悦朗, 溝上雅史:B型慢性肝炎の病態と治療-特にHBV genotypeとの関連について-. 日消誌 102:665-672, 2005.
 
13) 松嶋喬, 髭修平:HBVキャリアの長期予後. B型肝炎の新しい展開(犬山シンポジウム記録刊行会編), p31-34, アークメディア, 2001.
 
14) Yim HJ, Lok AS:Natural history of chronic hepatitis B:what we knew in 1981 and what we knew in 2005. Hepatology 43:S173-S181, 2006.
PubMed
15) 坪内博仁ほか:免疫抑制剤・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告-. 肝臓 50:38-42, 2009.
 
P.444 掲載の参考文献
1) 国立病院機構共同研究:本邦におけるウイルス性急性肝炎の発生状況と治療法に関する研究;平成21年度報告書(主任研究者八橋弘), 2010.
 
2) Orito E, et al:Geographic distribution of hepatitis B virus(HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594, 2001.
PubMed
3) 中尾留美子ほか:B型急性肝炎とHBVキャリア急性増悪のCLIA法IgM-HBc抗体価による判別. 肝臓 47:279-282, 2006.
 
4) Kusumoto K, et al:Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. J Gastroenterol Hepatol 23(5):790-793, 2008.
PubMed
5) Lin ZM, et al:Hepatitis B Virus of genotype C persistence after recovery from acute hepatitis B virus infection in Japan. Hepatol Res 25:244-253, 2003.
PubMed
6) Akahane Y, et al:Persistence of hepatitis B viremia after recovery from acute hepatitis B:correlation between anti-HBc titer and HBV DNA in serum. Hepatol Res 24:8, 2002.
PubMed
7) 矢野公士, 八橋弘:高齢者急性肝炎, 劇症肝炎の実態と対策. 肝胆膵 53:95-100, 2006.
Medical*Online
8) Aritomi T, et al:Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan. J Gastroenterol Hepatol 13(11):1125-1132, 1998.
PubMed
9) Tassopoulos NC, et al:Recombinant interferon-alpha therapy for acute hepatitis B:a randomized, double-blind, placebo-controlled trial. J Viral Hepat 4:387-394, 1997.
 
10) Kumar M, et al:A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 45:97-101, 2007.
 
P.451 掲載の参考文献
1) 持田智, 藤原研司:今月のテーマ「劇症肝炎, LOHFの現況」:我が国における劇症肝炎, LOHFの実態 日消誌 99:895-904, 2002.
 
2) 鈴木一幸ほか:劇症肝炎及び急性肝炎重症型の予後に関するprospective study.厚生労働省特定疾患対策研究事業「難治性の肝疾患に関する研究」班, 平成13年度報告書, p87-96, 2002.
 
3) Umemura T, Kiyosawa K:Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 45:747-748, 2006.
 
4) Fujiwara K, et al:Intractable Liver Diseases Study Group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 38:646-657, 2008.
 
5) 坪内博仁, 桶谷真:劇症肝炎及び遅発性肝不全(LOHF:late onset hepatic failure)の全国集計(2004年). 厚生労働科学研究費補助金(難治性疾患克服研究事業)「難治性の肝・胆道疾患に関する 調査研究班」平成17年度報告書, p61-69, 2006.
 
6) 坪内博仁ほか:劇症肝炎及び遅発性肝不全(LOHF:late onset hepatic failure)の全国集計(2005年). 厚生労働科学研究費補助金(難治性疾患克服研究事業)「難治性の肝・胆道疾患に関する調査研究班」平成18年度報告書, p90-100, 2007.
 
7) 坪内博仁ほか:劇症肝炎及び遅発性肝不全(LOHF:late onset hepatic failure)の全国集計(2006年). 厚生労働科学研究費補助金(難治性疾患克服研究事業)「難治性の肝・胆道疾患に関する調査研究班」平成19年度報告書, p83-94, 2008.
 
8) 坪内博仁ほか:劇症肝炎及び遅発性肝不全(LOHF:late onset hepatic failure)の全国集計(2007年). 厚生労働科学研究費補助金(難治性疾患克服研究事業)「難治性の肝・胆道疾患に関する調査研究班」平成20年度報告書, p83-93, 2009.
 
9) 坪内博仁ほか:劇症肝炎及び遅発性肝不全(LOHF:late onset hepatic failure)の全国集計(2008年). 厚生労働科学研究費補助金(難治性疾患克服研究事業)「難治性の肝・胆道疾患に関する調査研究班」平成21年度報告書, p95-106, 2010.
 
10) 持田智ほか:我が国の劇症肝炎, LOHFにおけるHEV感染の意義:全国集計からの検討. 厚生労働省肝炎等克服緊急対策事業「本邦に於けるE型肝炎の診断・予防・疫学に関する研究」班, 平成15年度報告書, p33-34, 2004.
 
11) 藤原研司ほか:B型肝炎ウイルスキャリアの急性増悪例に対するラミブジンの有効性に関するpro-spective study. 厚生労働省特定疾患対策研究事業「難治性の肝疾患に関する研究」班, 平成15年度研究報告書, p107-113, 2004.
 
12) 坪内博仁ほか:免疫抑制・化学療法により発症するB型肝炎対策:厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療標準化に関する研究」班合同報告. 肝臓 50:38-42, 2009.
 
13) Hui CK, et al:Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients under-going cytotoxic chemotherapy. Gastroenterology 131:59-68, 2006.
 
14) 持田智:免疫抑制薬, 抗悪性腫瘍薬によるB型肝炎再活性化の実態解明と対策法の確立. 厚生労働科学研究費補助金肝炎等克服緊急対策事業(肝炎分野), 平成21年度研究報告書, 2010.
 
15) 藤原研司, 持田智:肝炎劇症化の機序. <Editorial>. 肝臓 43:341-351, 2002.
 
16) 杉本潤一ほか:わが国における劇症肝炎の予後予測と肝移植の適応に関する多施設研究:日本急性肝不全研究会1996年肝移植適応ガイドライン策定の経緯. 肝臓 42:543-556, 2001.
 
17) Mochida S, et al:Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol Res 38:970 -979, 2008.
 
18) 持田智:劇症肝炎:わが国における問題点. 肝臓 50:497-502, 2009.
 
P.456 掲載の参考文献
1) 厚生労働省ホームページ (http://wwwmhlw.go.jp/houdou/2007/10/h1003-1.html)
 
2) Tanaka J, et al:Sex-and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3, 485, 648 first-time blood donors during 1995-2000. Intervirology 47:32-40, 2004.
 
3) Yoshikawa A, et al;Japanese Red Cross HBV Genotype Research Group:Age-and gender-specific distributions of hepatitis B virus(HBV) genotypes in Japanese HBV-positive blood donors.Transfusion 49:1314-1320, 2009.
 
4) Orito E, et al:Geographic distribution of hepatitis B virus(HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594, 2001.
PubMed
5) Matsuura K et al:Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 47:1476-1483, 2009.
 
6) World Health Organization, Department of Communicable Disease Surveillance and Response. Hepatitis B(WHO/CDS/CSR/LYO/2002.2). (http://www.who.int/emc, 2002)
 
7) Orito E, et al:A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33:218-223, 2001.
 
8) Nakayoshi T, et al:Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands:a prospective study. J Med Virol 70:350-354, 2003.
PubMed
9) Sanchez-Tapias JM, et al:Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 123:1848-1856, 2002.
 
P.461 掲載の参考文献
1) 内田俊和:ウイルス性肝炎. 病理と臨床 10:1224-1246, 1998.
 
2) Hoofnagle JH, et al:Management of hepatitis B:summary of a clinical research workshop. Hepatology 45:1056-1075, 2007.
PubMed
3) 市田文弘ほか:慢性肝炎の肝組織診断基準-新犬山分類-. C型肝炎研究の進歩, 肝炎ウイルスの変異, 犬山分類の再検討. 犬山シンポジウム記録刊行会(編), p183-188, 中外医学社, 1995.
 
4) De Franchis R, et al:The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 118:191-194, 1993.
PubMed
5) Hadziyannis SJ:Hepatitis B e antigen negative chronic hepatitis B:from clinical recognition to pathogenesis and treatment. Viral Hep Rev 1:7-36, 1995.
 
6) Hadziyannis SJ, Vassilopoulos D:Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34:617-624, 2001.
PubMed
7) Oikawa T, et al:Multistep and multicentric development of hepatocellular carcinoma:histological analysis of 980 resected nodules. J Hepatol 42:225-229, 2005.
PubMed
P.467 掲載の参考文献
1) McMahon BJ, et al:Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 135(9):759-768, 2001.
PubMed
2) Di Marco V, et al:The long-term course of chronic hepatitis B. Hepatology 30(1):257-264, 1999.
 
3) Yu MW, et al:Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 145(11):1039-1047, 1997.
PubMed
4) Yokosuka O, et al:Management of hepatitis B:Consensus of the Japan Society of Hepatology 2009. Hepatol Res 41(1):1-21, 2011.
PubMed
5) Iloeje UH, et al:Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130(3):678-686, 2006.
PubMed
6) Chen CH, et al:Clinical significance of hepatitis B virus(HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol 43(12):6000-6006, 2005.
PubMed
7) Lindh M, et al:Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 179(4):775-782, 1999.
PubMed
8) Kao JH, et al:Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118(3):554-559, 2000.
PubMed
9) Chen CH, et al:Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 133(5):1466-1474, 2007.
 
10) Fernandez-Esparrach G, et al:A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 34(1):46-52, 2001.
PubMed
11) Kim SU, et al:Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol 23(11):1722-1727, 2008.
PubMed
12) Niederau C, et al:Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334(22):1422-1427, 1996.
PubMed
13) Lau DT, et al:Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113(5):1660-1667, 1997.
PubMed
14) van Zonneveld M, et al:Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39(3):804-810, 2004.
PubMed
15) Papatheodoridis GV, et al:Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42(1):121-129, 2005.
PubMed
16) Dienstag JL, et al:Histological outcome during long-term lamivudine therapy. Gastroenterology 124(1):105-117, 2003.
PubMed
17) Liaw YF, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521-1531, 2004.
PubMed
18) Chang Tr, et al:Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52(3):886-893, 2010.
 
19) Livingston SE, et al:Clearance of hepatitis B e antigen in patients with chronic hepatitis B and geno-types A, B, C, D, and F. Gastroenterology 133(5):1452-1457, 2007.
 
20) Liaw YF, et al:Hepatitis B e antigen seroconversion:a critical event in chronic hepatitis B virus infection. Dig Dis Sci 55(10):2727-2734, 2010.
PubMed
21) Chu CM, et al:Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol 8(6):535-540, 2010.
PubMed
22) Chen JD, et al:Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138(5):1747-1754, 2010.
 
23) Chu CJ, et al:Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 36(6):1408-1415, 2002.
PubMed
24) Martinot-Peignoux M, et al:Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 36(4):543-546, 2002.
PubMed
25) Bekku D, et al:Long-term follow-up in patients with hepatitis B e antigen negative chronic hepatitis B. J Gastroenterol Hepatol 26(1):122-128, 2011.
PubMed
26) Hoofnagle JH, et al:Management of hepatitis B:summary of a clinical research workshop. Hepatology 45:1056-1075, 2007.
PubMed
27) Feld JJ, et al:Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 46:1057-1070, 2007.
PubMed
28) Liu J, et al:Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance:a community-based follow-up study. Gastroenterology 139(2):474-482, 2010.
PubMed
29) Chen CJ, et al:Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65-73, 2006.
PubMed
30) Ohata K, et al:High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 19:670-675, 2004.
 
31) Murata K, et al:Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection. World J Gastroenterol 11:6848-6852, 2005.
PubMed
32) Mahmood S, et al:Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 25:220-225, 2005.
PubMed
33) Ishikawa T, et al:High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 16:1274-1281, 2001.
PubMed
34) Ito K, et al:Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol 45(2):243-249, 2010.
PubMed
35) Chen CL, et al:Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection:a follow-up study in Taiwan. Gastroenterology 135(1):111-121, 2008.
PubMed
36) Loomba R, et al:Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol 8(10):891-898, 898.el-2, 2010.
 
37) Larsson SC, Wolk A:Coffee consumption and risk of liver cancer:a metaanalysis. Gastroenterology 132:1740-1745, 2007.
 
38) Liu S, et al:Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma:a meta-analysis. J Natl Cancer Inst 101(15):1066-1082, 2009.
PubMed
39) Yeh CT, et al:Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology 52 (6):1922-1933, 2010.
PubMed
40) Wong DK, et al:Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119(4):312-323, 1993.
PubMed
41) Lau GK, et al:Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352(26):2682-2695, 2005.
PubMed
P.474 掲載の参考文献
1) Kumada H, et al:Short-term prednisolone for inducing seroconversion from hepatitis e antigen to antibody along with clinical improvement in patients with chronic active hepatitis type B. JPn J Med 26:217-222, 1987.
PubMed
2) Liaw YF, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 341:1521-1530, 2004.
 
3) Matsumoto A, et al:Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B:A multicenter retrospective study of 2795 patients. Hepatol Res 32:173-184, 2005.
PubMed
4) Iloeje UH, et al:Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678-686, 2006.
PubMed
5) Chen CJ, et al:Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73, 2006.
PubMed
6) Yuen MF, et al:Prognostic determinations for chronic hepatitis B in Asians:therapeutic implica-tions. Gut 54:1610-1614, 2005.
 
7) 熊田博光:肝硬変を含めたウイルス性肝疾患の治療法の標準化に関する研究. 厚生労働科学研究費肝炎等克服緊急対策研究 平成21年度研究報告書, p232-246, 2010.
 
8) Lok ASF, McMahon BJ:AASLD practice guidelines. Chronic hepatitis B:Update 2009. Hepatology 50:1-36, 2009.
 
9) Lindh M, et al:Treatment of chronic hepatitis B infection:An update of Swedish recommendation. Scan J Infect Dis 40:436-450, 2008.
 
P.478 掲載の参考文献
1) Hui CK et al:Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 46:395-401, 2007.
PubMed
2) Manno M, et al:Natural history of chronic HBV carriers in northern Italy:morbidity and mortality after 30 years. Gastroenterology 127:756-763, 2004.
PubMed
3) Chen YC, et al:Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 123:1084-1089, 2002.
PubMed
4) Arase Y, et al:Long-term outcome after HBsAg seroclearance in patients with chronic hepatitis B. Am J Med 119:e9-16, 2006.
PubMed
5) Liaw YF, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004.
PubMed
6) Matsumoto A, et al:Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B:A multicenter retrospective study of 2795 patients. Hepatol Res 32:173-184, 2005.
PubMed
7) Niederau C, et al:Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334:1422-1427, 1996.
PubMed
8) Suzuki F, et al:Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol 39:969-974, 2004.
PubMed
9) Chayama K, et al:Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716, 1998.
PubMed
10) Tenney DJ, et al:Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49:1503-1514, 2009.
PubMed
11) Hadziyannis SJ, et al:Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348:800-807, 2003.
PubMed
12) Marcellin P, et al:Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepa-titis B. N Engl J Med 348:808-816, 2003.
 
13) Orito E, et al:A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33:218-223, 2001.
 
14) Hosaka T, et al:Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 42:368-374, 2007.
PubMed
15) Yatsuji H, et al:Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy:Two-year follow-up. J Hepatol 48:923-931, 2008.
PubMed
P.485 掲載の参考文献
1) Randall RE, Goodbourn S:Interferons and viruses:an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89:1-47, 2008.
PubMed
2) Kumada H, et al:Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 40:1-7, 2010.
PubMed
3) 髭修平ほか:B型慢性肝炎のインターフェロン治療例における長期予後. 臨床消化器内科 14:1405-1410, 1999.
 
4) 髭修平ほか:新しいB型肝炎ウイルスのマーカー:HBコア関連抗原. 臨床消化器内科 24:609-614, 2009.
 
5) Suzuki F, et al:Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 81:27-33, 2009.
PubMed
6) Lau GK, et al:Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:2682-2695, 2005.
PubMed
7) Janssen HL, et al:Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial. Lancet 365:123-129, 2005.
 
8) Marcellin P, et al:Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351:1206-1217, 2004.
PubMed
9) Kaymakoglu S, et al:Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus e antigen-negative chronic hepatitis B. Antimicrob Agents Chemother 51:3020-3022, 2007.
PubMed
10) Schalm SW, et al:Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection:a randomised trial. Gut 46:562-568, 2000.
PubMed
11) Woo G, et al:Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139:1218-1229, 2010.
PubMed
12) Liaw YF, et al:Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172-180, 2000.
PubMed
P.491 掲載の参考文献
1) Seifer M, et al:In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 42:3200-3208, 1998.
 
2) Innaimo S, et al:Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 41:1444-1448, 1997.
 
3) Colonno RJ, et al:Long-term entecavir treatment results in sustained antiviral efficacy and pro-longed life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 184:1236-1245, 2001.
 
4) Chang TT, et al:Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51:422-430, 2010.
PubMed
5) Shouval D, et al:Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment:the case for continuous antiviral therapy. J Hepatol 50:289-295, 2009.
PubMed
6) Kobashi H, et al:Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients:Phase II clinical study in Japan. J Gastroenterol Hepatol 24:262-269, 2009.
 
7) Yokosuka O, et al:Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 52:791-799, 2010.
PubMed
8) Sherman M, et al:Entecavir therapy for lamivudine-refractory chronic hepatitis B:improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48(1):99-108, 2008.
PubMed
9) Karino Y, et al:Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int 4:414-422, 2010.
PubMed
10) Chang Tr, et al:Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52:886-893, 2010.
 
11) Tenney DJ, et al:Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleo-side-naive patients is rare through 5 years of therapy. Hepatology 49:1503-1514, 2009.
 
12) Kobashi H, et al:Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 3:403-410, 2009.
PubMed
13) 熊田博光:厚生労働科学研究費補助金肝炎等克服緊急対策研究事業(肝炎分野) 肝硬変を含めたウイルス性肝疾患の治療の標準化に関する臨床的研究. 平成21年度総括・分担研究報告書, 2010.
 
P.497 掲載の参考文献
1) Dienstag JL, et al:A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661, 1995.
PubMed
2) Lai CL, et al:A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68, 1998.
PubMed
3) Leung NW, et al:Extended lamivudine treatment in patients with chronic hepatitis B enhances hepa-titis B e antigen seroconversion rates:Results after 3 years of therapy. Hepatology 33:1527-1532, 2001.
 
4) Santantonio T, et al:Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 32:300-306, 2000.
PubMed
5) Marco VD, et al:Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40:883-891, 2004.
 
6) Liaw YF, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004.
PubMed
7) Lok ASF, et al:Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722, 2003.
 
8) Sherman M, et al:Entecavir therapy for lamivudine-refractory chronic hepatitis B:Improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48:99-108, 2008.
PubMed
9) Marcellin P, et al:Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis Beantigen-positive chronic hepatitis B. Hepatology 48:750-758, 2008.
 
10) Hadziyannis SJ, et al:Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131:1743-1751, 2006.
PubMed
11) Lee YS, et al:Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43:1385-1391, 2006.
PubMed
12) Rapti I, et al:Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45:307-313, 2007.
PubMed
13) Peters MG, et al:Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126:91-101, 2004.
PubMed
14) Lampertico P, et al:Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42:1414-1419, 2005.
PubMed
15) Lampertico P, et al:Low resistance to adefovir combined with lamivudine:A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451, 2007.
PubMed
P.501 掲載の参考文献
1) Serfaty L et al:Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone:results of a pilot study. Hepatology 34:573-577, 2001.
 
2) Manesis EK, et al:A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepa-titis B. Aliment Pharmacol Ther 23:99-106, 2006.
 
3) Shi M, et al:Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother 58:1031-1035, 2006.
PubMed
4) Vassiliadis T, et al:Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J Gastroenterol Hepatol 22:1582-1588, 2007.
PubMed
5) Moucari R, et al:Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. J Viral Hepat, 2010. (Epub ahead of print)
 
6) Minami M, Okanoue T:Management of HBV infection in Japan. Hepatol Res 37:S79-82, 2007.
PubMed
7) Enomoto M, et al:Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. J Interferon Cytokine Res 27:201-207, 2007.
PubMed
8) Okuse C, et al:Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B. Hepatol Res 40:461-469, 2010.
 
9) Kumada H, et al:Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 40:1-7, 2010.
PubMed
P.506 掲載の参考文献
1) 恩地森一:B型肝炎ウイルス感染症肝疾患と肝免疫, p39-50, 中外医学社, 2008.
 
2) Maini MK, et al:The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191:1269-1280, 2000.
PubMed
3) Horiike N, et al:Activation and maturation of antigen-presenting dendritic cells during vaccine therapy in patients with chronic hepatitis due to hepatitis B virus. Hepatol Res 23:38-47, 2002.
PubMed
4) Pol S, et al:Specific vaccine therapy in chronic hepatitis B infection. Lancet 344:342, 1994.
PubMed
5) Horiike N, et al:In vivo immunization by vaccine therapy following Virus suppression by lamivudine:a novel approach for treating patients with chronic hepatitis B. J Clin Virol 32:156-161, 2005.
PubMed
6) Betancourt AA et al:Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 11:394-401, 2007.
PubMed
7) Fazle Akbar SM, et al:A Therapeutic nasal vaccine containing HBsAg and HBcAg was safe, had an-tiviral potential and induced antigen-specific immunity in patients with chronic hepatitis B. Hepatol Int 4:159-160, 2010. (Abstract)
 
8) Mancini-Bourgine M, et al:Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24(21):4482-4489, 2006.
PubMed
9) Onji M, Akbar SMF:Dendritic Cells in Clinics, 2nd ed, Springer, Tokyo, 2008.
 
10) Fazle Akbar SM, et al:Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 29:136-141, 2004.
PubMed
11) Fazle Akbar SM, et al:Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J Hepatol 47:60-66, 2007.
PubMed
12) Fazle Akbar SM, et al:Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B. J Viral Hepat, 2010. (Epub ahead of print)
 
13) Lau GK, et al:Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122:614-624, 2002.
PubMed
14) van Nunen AB, et al:Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients. Liver 21:207-212, 2001.
PubMed
15) Xu DZ, et al:A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 3:e2565, 2008.
PubMed
P.510 掲載の参考文献
1) B型肝炎. 慢性肝炎の治療ガイド2008(日本肝臓学会), p4-19, 文光堂, 2007.
 
2) 黒崎雅之, 泉並木:Lamivudine長期投与治療成績と長期予後. コンセンサス肝疾患2007(岡上武ほか), p22-26, 日本メディカルセンター, 2007.
 
3) 今村道雄, 茶山一彰:薬剤抵抗性株出現時の対応と問題点. 肝胆膵 58(5):585-590, 2009.
Medical*Online
4) Lee YS, et al:Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43:1385-1391, 2006.
PubMed
5) Lampertico P, et al:Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451, 2007.
PubMed
6) Brunelle MN, et al:Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41:1391-1398, 2005.
PubMed
7) Sherman M, et al:Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130:2039-2049, 2006.
PubMed
8) 片野義明ほか:ラミブジン治療で十分な抗ウイルス効果が得られなかった成人B型慢性肝炎患者に対するEntecavir経口投与の検討 有効性・安全性に関する臨床第II相試験. 肝臓 47(1):A152, 2006.
 
9) 緒方啓ほか:耐性ウイルスに対して. 肝胆膵 56(5):741-747, 2008.
Medical*Online
10) Schildgen O, et al:Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354:1807-1812, 2006.
PubMed
11) Hadziyannis SJ, et al:Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131:1743-1751, 2006.
PubMed
12) Yatsuji H, et al:Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy:two-year follow-up. J Hepatol 48:923-931, 2008.
PubMed
13) 中尾将光ほか:Lamivudine, Adefovir, Entecavirがすべて無効のHBV株に対するTenofovirを用いた抗ウイルス療法. 消化器科 47(4):450-453, 2008.
 
14) Patterson SJ, et al:Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut, 2010. (Epub ahead of print)
 
P.514 掲載の参考文献
1) 熊田博光:厚生労働科学研究費補助金, 肝炎等克服緊急対策研究事業(肝炎分野), 肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究, 平成21年度総括・分担研究報告書, 平成22年3月.
 
2) Suzuki F, et al:Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol 39:969-974, 2004.
PubMed
3) Suzuki F, et al:Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 46:182-189, 2003.
PubMed
4) Akuta N, et al:Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan:comparison with breakthrough hepatitis during long-term treatment. Intervirology 48:174-182, 2005.
PubMed
5) Marcellin P, et al:Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442-2455, 2008.
PubMed
6) Heathcote EJ, et al:Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. (in press)
 
7) Liaw YF, et al:Tenofovir disoproxil fumarate(TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. (in press)
 
8) Bommel FV, et al:Tenofovir for patients with lamivudine-resistant hepatitis B virus(HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44:318-325, 2006.
 
9) Tan J, et al:Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 48:391-398, 2008.
PubMed
10) Bommel FV, et al:Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:73-80, 2010.
 
11) Patterson SJ, et al:Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. (in press)
 
12) Lim SG, et al:A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 166:49-56, 2006.
PubMed
13) Berg T, et al:Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139:1207-1217, 2010.
 
14) Yoo BC, et al:Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 45:1172-1178, 2007.
PubMed
15) Lai CL, et al:Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357:2576-2588, 2007.
PubMed
P.518 掲載の参考文献
1) Raimondo G, et al:Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652-657, 2008.
PubMed
2) Zerbini A et al:The characteristics of the cell-mediated immune response identify dfferent profiles of occult hepatitis B virus infection. Gastroenterology 134:1470-1481, 2008.
 
3) Brechot C, et al:Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen:clinically significant or purely "occult"? Hepatology 34:194-203, 2001.
PubMed
4) Torbenson M, Thomas DL:Occult hepatitis B. Lancet lnfect Dis 2:479-486, 2002.
PubMed
5) Yuen ME et al:Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B:a study of a large blood donor population, Gut 59:1389-1393, 2010.
 
6) Allain JP, et al:Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 49:1868-1876, 2009.
PubMed
7) Lok AS, et al:Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188, 1991.
PubMed
8) Uemoto S, et al:Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 65:494 -499, 1998.
 
9) Dervite I, et al:Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68-69, 2001.
 
10) Hui CK, et al:Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients under-going cytotoxic chemotherapy. Gastroenterology 131:59-68, 2006.
 
11) Yeo W, et al:Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611, 2009.
PubMed
12) Umemura T, et al:Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52-56, 2008.
PubMed
13) Cacciola I, et al:Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.N Engl J Med 341:22-26, 1999.
PubMed
14) Vivekanandan P, et al:Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 46:1227-1236, 2008.
PubMed
P.525 掲載の参考文献
1) 坪内博仁ほか:免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告-. 肝臓 50:38-42, 2009.
 
2) Lau GK, et al:Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742-1749, 2003.
PubMed
3) Hsu C, et al:A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma:a randomized trial. Hepatology 47:844-853, 2008.
 
4) Lok AS, McMahon BJ:Chronic hepatitis B. Hepatology 45:507-539, 2007.
PubMed
5) Michalak TI, et al:Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 93:230-239, 1994.
PubMed
6) Raimondo G, et al:Occult hepatitis B virus infection. J Hepatol 46:160-170, 2007.
PubMed
7) Lok AS, et al:Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92:1839-1843, 1987.
PubMed
8) Hui CK, et al:Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients under-going cytotoxic chemotherapy. Gastroenterology 131:59-68, 2006.
 
9) Umemura T, et al:Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52-56, 2008.
PubMed
10) Kusumoto S, et al:Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13-23, 2009.
PubMed
11) Yeo W, et al:Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000.
PubMed
12) Liaw YF:Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 13:14-20, 1998.
PubMed
13) Hsu CH, et al:Doxorubicin activates hepatitis B virus(HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 24:3035-3040, 2004.
 
14) Zingarelli S, et al:Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients:reports of 3 cases and review of the literature. J Rheumatol 36:1188-1194, 2009.
PubMed
15) Steinberg JL, et al:Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours:precore/core mutations may play an important role. J Med Virol 60:249-255, 2000.
 
P.528 掲載の参考文献
1) Fontana RJ, et al:Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 123:719-727, 2002.
PubMed
2) Kim WR et al:Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 137:1680-1686, 2009.
PubMed
3) Angus PW, Patterson SJ:Liver transplantation for hepatitis B:what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl 14:S15-S22, 2008.
PubMed
4) Gane EJ, et al:Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132:931-937, 2007.
PubMed
5) Hooman N, et al:Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 14:435-442, 2008.
 
6) Buti M, et al:Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 84:650-654, 2007.
 
7) Schiff E, et al:Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B:final long-term results. Liver Transpl 13:349-360, 2007.
PubMed
8) Rapti I, et al:Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatits B. Hepatology 45:307-313, 2007.
 
9) Lampertico P, et al:Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451, 2007.
PubMed
10) Angus PW, et al:A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 48:1460-1466, 2008.
PubMed
11) Teperman L, et al:Emtricitabine/tenofovir combination+/-HBIG post-orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment. J Hepato1 52:S12-S13, 2010.
 
12) Lo CM, et al:Failure of HBV vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 43:283-287, 2005.
PubMed
13) Gunther M, et al:Immunization with an adjuvant HBV vaccine in liver transplant recipients. Liver Transpl 12:316-319, 2006.
PubMed
14) Lo CM, et al:Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for HBV. Am J Transplant 7:434-439, 2007.
 
15) Gane E:Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B:High, low or no dose? Liver Transpl 16:S36-S39, 2010.
PubMed
P.533 掲載の参考文献
1) Koike K et al:Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res 38:310-314, 2008.
PubMed
2) Gatanaga H, et al:Drug-resistant HIV-1 prevalence in patients newly diagnosed with HrV/AIDS in Japan. Antiviral Res 75:75-82, 2007.
 
3) Orito E, et al:Geographic distribution of hepatitis B virus(HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594, 2001.
PubMed
4) Sugauchi F, et al:Spatial and chronological differences in hepatitis B Virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res 36:107-114, 2006.
PubMed
5) Koibuchi T, et al:Predominant of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan. J Med Virol 64:435-440, 2001.
 
6) Gatanaga H, et al:Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. Eur J Clin Microbiol Infect Dis 19:237-239, 2000.
 
7) McMahon MA, et al:The HBV drug entecavir-effects on HIV-1 replication and resistance. N Engl J Med 356:2614-2621, 2007.
PubMed
8) DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents:Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1:1-161, 2009. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
 
9) Centers for Disease Control and Prevention. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-infected Children. MMWR Early Release 58:1-166, 2009.
 
P.538 掲載の参考文献
1) Murakami S:Hepatitis B virus X protein:structure, function and biology. Intervirology 42:81-99, 1999.
PubMed
2) Bouchard MJ, et al:Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 294:2376-2378, 2001.
PubMed
3) Nakamoto Y, et al:Immune pathogenesis of hepatocellular carcinoma. J Exp Med 188:341-350, 1998.
PubMed
4) Nakamoto Y, Kaneko S:Mechanisms of viral hepatitis induced liver injury. Curr Mol Med 3:537-544, 2003.
PubMed
5) Nakamoto Y, et al:Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B. Cancer Res 64:3326-3333, 2004.
 
6) Nakamoto Y, Kaneko S:Analysis of intrahepatic lymphocyte subsets in a transgenic mouse model of immunemediated hepatocarcinogenesis. J Exp Clin Cancer Res 25:55-57, 2006.
 
7) Nakamoto Y, et al:Difiierential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 158:5692-5697, 1997.
PubMed
8) Nakamoto Y, et al:Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med 196:1105-1111, 2002.
PubMed
9) Chen JD, et al:Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138:1747-1754, 2010.
 
10) Wong VW, et al:Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 28:1660-1665, 2010.
PubMed
11) Zhang H, et al:Genome-wide association study identifies lp36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 42:755-758, 2010.
 
12) Kota J, et al:Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-1017, 2009.
 
13) Ji J, et al:MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361:1437-1447, 2009.
PubMed
P.545 掲載の参考文献
1) Yim HJ, Lok AS:Natural history of chronic hepatitis B virus infection:what we knew in 1981 and what we know in 2005. Hepatology 43:S173-S181, 2006.
PubMed
2) Chen CJ, et al:Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73, 2006.
PubMed
3) Ishikawa T, et al:High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gas-troenterol Hepato1 16:1274-1281, 2001.
 
4) Ikeda K, et al:Consistently low hepatitis B virus DNA saves patients from hepatoceilular carcino-genesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients. Intervirology 46:96-104, 2003.
 
5) Ohata K, et al:High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 19:670-675, 2004.
 
6) Mazzella G, et al:Long-term results with interferon therapy in chronic type B hepatitis:a prospective randomized trial. Am J Gastroenterol 94:2246-2250, 1999.
PubMed
7) Mazzella G, et al:Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141-147, 1996.
PubMed
8) Lin SM, et al:Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46:45-52, 2007.
PubMed
9) Di Marco V, et al:The long-term course of chronic hepatitis B. Hepatology 30:257 -264, 1999.
 
10) Benvegnu L, et al:Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83:901-909, 1998.
 
11) Ikeda K, et al:Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus:a pilot study. Cancer 82:827-835, 1998.
PubMed
12) Brunetto MR, et al:Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma:A retrospective cohort study. Lancet 351:1535-1539, 1998.
 
13) Fattovich G, et al:Delayed clearance of serum HBsAg in compensated cirrhosis B:relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis(EUROHEP). Am J Gastroenterol 93:896-900, 1998.
PubMed
14) Camma C, et al:Interferon and prevention of hepatocellular carcinoma in viral cirrhosis:an evidence-based approach. J Hepatol 34:593-602, 2001.
PubMed
15) Sung JJ, et al:Meta-analysis:treatment of hepatitis B infection reduces of risk of hepatocellular carcinoma. Aliment Pharmacol Ther 28:1067-1077, 2008.
PubMed
16) Liaw YF, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004.
PubMed
17) Yuen MF, et al:Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 12:1295-1303, 2007.
PubMed
18) Matsumoto A, et al:Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B:A multicenter retrospective study of 2795 patients. Hepatol Res 32:173-184, 2005.
PubMed
19) Eun JR, et al:Risk assessment for the development of hepatocellular carcinoma:According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 53:118-125, 2010.
 
20) Sung JJ, et al:Meta-analysis:Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 28:1067-1077, 2008.
PubMed
P.550 掲載の参考文献
1) 肝癌診療マニュアル(日本肝臓学会編), 第2版, 医学書院2010.
 
2) 日本肝癌研究会(編):第18回原発性肝癌全国調査.
 
3) Liaw YF, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004.
PubMed
4) Matsumoto A, et al:Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B:A multicenter retrospective study of 2795 patients. Hepatol Res 32:173-184, 2005.
PubMed
5) Lin SM, et al:Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29:971-975, 1999.
PubMed
6) Ikeda K, et al:Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus:A pilot study. Cancer 82:827-835, 1998.
PubMed
7) Camma C, et al:Interferon and prevention of hepatocellular carcinoma in viral cirrhosis:An evidence-based approach. J Hepatol 34:593-602, 2001.
PubMed

IV A型肝炎

P.558 掲載の参考文献
1) Xu ZY, et al:Ecology and prevention of a shellfish-associated hepatitis A epidemic in Shanghai, China. Vaccine 10(Suppl 1):S67-S68, 1992.
 
2) Wheeler C, et al:An outbreak of hepatitis A associated with green onions. N Engl J Med 353:890-897, 2005.
PubMed
3) Niu MT, et al:Multistate outbreak of hepatitis A associated with frozen strawberries. J Infect Dis 166(3):518-524, 1992.
PubMed
4) Henning KJ, et al:A community-wide outbreak of hepatitis A:risk factors for infection among homosexual and bisexual men. Am J Med 99(2):132-136, 1995.
PubMed
5) Ida S, et al:Rate of subclinical hepatitis A virus infection in adult HIV-1-infected patients. Jpn J Infect Dis 54(1):31-32, 2001.
PubMed
6) 矢野公士(主任研究者):国立病院機構共同研究:本邦における急性肝炎の疫学調査および欧米型B型(genotypeA)肝炎とE型肝炎の発生状況に関する研究, 平成21(2009)年3月.
 
7) 矢野公士(研究代表者):厚生労働科学研究費 肝炎等克服緊急対策研究事業:経口感染する肝炎ウイルス(A型, E型)の感染防止, 遺伝的多様性, および治療に関する研究. 平成21年度報告書, 平成22(2010)年4月.
 
8) Yano K, et al:Dynamic epidemiology of acute viral hepatitis in Japan. Intervirology 53:70-77, 2010.
PubMed
9) 矢野公士, 八橋 弘:A型肝炎の疫学的変遷. 肝胆膵 47(5):611-616, 2003.
Medical*Online
10) Lee D, et al:Hepatitis A in Korea:epidemiological shift and call for vaccine strategy. Intervirology 51:70-74, 2008.
PubMed
11) Kwon SY:Current status of liver diseases in Korea:hepatitis A. Korean J Hepatol 15(SuppI 6):S7-12, 2009.
 
12) Kim YJ, Lee HS:Increasing incidence of hepatitis A in Korean adults. Intervirology 53:10-14, 2010.
PubMed
13) Jeong SH:Current status and vaccine indication for hepatitis A virus infection in Korea. Korean J Gastroenterol 51(6):331-337, 2008.
PubMed
14) Yoon YK, et al:Epidemiological and genetic analysis of a sustained community-wide outbreak of hepatitis A in the Republic of Korea, 2008:A hospital-based case-control study. J Clin Virol 46(2):184-188, 2009.
PubMed
P.565 掲載の参考文献
1) Feinstone SM, et al:Hepatitis A:detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 182:1026-1028, 1973.
PubMed
2) Hollinger FB, Emerson SU:Hepatitis A virus. In:Fields Virology(ed by Knipe DM, et al), p911-947, Lippincott Williams & Wilkins, Philadelphia, 2007.
 
3) Glass MJ, et al:Identification of the hepatitis A virus internal ribosome entry site:in vivo and in vitro analysis of bicistronic RNAs containing the HAV 5/noncoding region. Virology 193:842-852, 1993.
PubMed
4) Probst C, et al:Intrinsic signals for the assembly of hepatitis A virus particles:Role of structural proteins VP4 and 2A. J Biol Chem 274:4527-4531, 1999.
PubMed
5) Malcolm BA, et al:Expression and characterization of recombinant hepatitis A virus 3 C proteinase. Biochemistry 31:3358-3363, 1992.
 
6) Weitz M, et al:Detection of a genome-linked protein(VPg) of hepatitis A virus and its comparison with other picornaviral VPgs. J Virol 60:124-130, 1986.
PubMed
7) Lemon SM, et al:Why do human hepatitis viruses replicate so poorly in cell cultures? FEMS Microbiol Lett 79:455-459, 1992.
 
8) Aragones L, et al:Fine-tuning translation kinetics selection as the driving force of codon usage bias in the hepatitis A virus capsid. PLoS Pathog 6:e1000797, 2010.
PubMed
9) Kaplan G, et al:Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J 15:4282-4296, 1996.
PubMed
10) Feigelstock D, et al:The human homolog of HAVcr-1 codes for hepatitis A virus cellular receptor. J Virol 72:6621-6628, 1998.
PubMed
11) McIntire JJ, et al:Hepatitis A virus link to atopic disease. Nature 425:576, 2003.
PubMed
12) Vallbracht A, et al:Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis 160:209-217, 1989.
PubMed
13) Maier K, et al:Human gamma interferon production by cytotoxic T lymphocyte sensitized during hepatitis A virus infection. J Virol 62:3756-3763, 1988.
PubMed
14) Yang Y, et al:Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci USA 104:7253-7258, 2007.
PubMed
15) Paulmann D, et al:Hepatitis A virus protein 2 B suppresses beta interferon(IFN) gene transcription by interfering with IFN regulatory factor 3 activation. J Gen Virol 89:1593-1604, 2008.
 
P.569 掲載の参考文献
1) 国立感染症研究所感染症情報センター:The Topic of This Month:Hepatitis A. Infectious agents surveillance report 31:284-285, 2010.
 
2) 長尾由実子, 佐田通夫:A型肝炎の現状と予防. 臨床と研究 85:24-28, 2008.
 
3) Takahashi H, et al:Molecular epidemiology of hepatitis A virus in metropolitan areas in Japan. J Gastroenterol 41:981-986, 2006.
PubMed
4) Kiyohara T, et al:Shifting seroepidemiology of hepatitis A in Japan, 1973-2003. Microbiol Immunol 51:185-191, 2007.
PubMed
5) Kim YJ, Lee HS:Increasing incidence of hepatitis A in Korean adults. Intervirology 53:10-14, 2010.
PubMed
6) Arteaga-Rodriguez A, et al:Changes in the epidemiology of hepatitis A in Spain(2005-2008):trends of acute hepatitis A hospitalizations, comorbidities, and costs associated with the hospitalization. Eur J Gastroenterol Hepatol 22:1284-1289, 2010.
PubMed
7) 国立感染症研究所感染症情報センター:A型肝炎2010年第1-28週速報.感染症発症動向調査, 2010.(http://idsc.nih.gojp./disease/hepatitisA/2010week28.html)
 
8) Sata M, et al:Analysis of serum hepatitis A virus antibody response in different courses of hepatitis A virus infection. J Gastroenterol 31:812-817, 1996.
PubMed
9) Fujiwara K, et al:Phylogenetic analysis of hepatitis A virus in sera from patients with hepatitis A of various severities. Liver Int 29:838-845, 2009.
PubMed
10) Jeong SH, Lee HS:Hepatitis A:clinical manifestations and management. Intervirology 53:15-19, 2010.
PubMed
11) Ide T, et al:Clinical evaluation of four cases of acute viral hepatitis complicated by pure red cell aplasia. Am J Gastroenterol 89:257-262, 1994.
PubMed
12) Koiso H, et al:Pure red cell aplasia accompanied by autoimmune hemolytic anemia in a patient with type A viral hepatitis. Rinsho Ketsueki 50:424-429, 2009.
 
13) Tokeshi S, et al:Secretory IgA anti-HAV in bile of hepatitis A patients. Hepatol Res 10:167-174, 1998.
 
14) Setoyama H, et al:Secretory IgA anti-HAV in saliva of hepatitis A patients. Hepatol Res 11:112-118, 1998.
 
15) 佐田通夫ほか:A型肝炎ウイルスの唾液中排泄について. 肝臓 125:423, 1984.
 
16) Amado LA, et al:Experimental hepatitis A virus(HAV) infection in cynomolgus monkeys(Macaca fascicularis):evidence of active extrahepatic site of HAV replication. Int J Exp Pathol 91:87-97, 2010.
PubMed
17) 野田衛ほか:自治体間におけるA型肝炎ウイルスの分子的, 疫学的データの共有体制(V-Nus Net Japan)の構築:その目的と意義. Infectious agents surveillance report 31:289-291, 2010.
 

V E型肝炎

P.577 掲載の参考文献
1) Colson P, et al:Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis 202(6):825-834, 2010.
PubMed
2) Jameel S, et al:Enteric non-A, non-B hepatitis:epidemics, animal transmission, and hepatitis E virus detection by the polymerase chain reaction. J Med Virol 37(4):263-270, 1992.
 
3) Balayan MS, et al:Evidence for a virus in non-A, non-B hepatitis transmitted via the fecaloral route. Intervirology 20:23-31, 1983.
 
4) Bradley D, et al:Aetiological agent of enterically transmitted non-A, non-B hepatitis. J Gen Virol 69:731-738, 1988.
 
5) Reyes GR et al:Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 247:1335-1339, 1990.
 
6) ICTV approved Virus Orders, Families and Genera. (http://www.ictvdb.iacr.ac.uk/Ictv/fr-fst-g.htm)
 
7) Chauhan A, et al:Hepatitis E virus transmission to a volunteer. Lancet 341:149-150, 1993.
PubMed
8) Khuroo MS, et al:Incidence and severity of viral hepatitis in pregnancy. Am J Med 70:252-255, 1981.
PubMed
9) Meng XJ, et al:A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci USA 94:9860-9865, 1997.
 
10) Tei S, et al:Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 362:371-373, 2003,
PubMed
11) Li TC, et al:Hepatitis E virus transmission from wild Boar Meat. Emerg Infect Dis 11(12):1958-1960, 2005.
PubMed
12) Li TC, et al:Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus. J Med Virol 62:327-333, 2000.
PubMed
13) Matsuura Y, et al:Prevalence of antibody to hepatitis E virus among wild sika deer, Cervus nippon, in Japan. Arch Virol 152(7):1375-1381, 2007.
PubMed
14) Zhao C, et al:A novel genotype of hepatitis E virus prevalent among farmed rabbits in China. J Med Virol 81(8):1371-1379, 2009.
 
15) 高橋和明ほか:従来未知の遺伝子型"genotype 5"を代表すると思われる野生猪由来E型肝炎ウイルス塩基配列. 肝臓 51:536-538, 2010.
 
P.586 掲載の参考文献
1) Balayan MS, et al:Evidence for a virus in non-A, non-B hepatitis transmitted via the fecaloral route. Intervirology 20:23-31, 1983.
 
2) Reyes GR et al:Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 247:1335-1339, 1990.
 
3) Kwo P, et al:Acute hepatitis E by a new isolate acquired in the United States. Mayo Clin Proc 72:1133-1136, 1997.
PubMed
4) Tanaka T, et al:Development and evaluation of an efficient cell-culture system for Hepatitis E virus. J Gen Virol 88:903-911, 2007.
PubMed
5) Takahashi M, et al:Hepatitis E virus(HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies:characterization of HEV virions in blood circulation. J Clin Microbiol 48:1112-1125, 2010.
PubMed
6) Yamashita T, et al:Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci USA 106:12986-12991, 2009.
PubMed
7) Yamada K, et al:ORF3 protein of hepatitis E virus is essential for virion release from infected cells.J Gen Virol 90:1880-1891, 2009.
 
8) Okamoto H:Genetic variability and evolution of hepatitis E virus. Virus Res 127:216-228, 2007.
PubMed
9) 高橋和明ほか:従前未知の遺伝子型"genotype 5"を代表すると思われる野生猪由来E型肝炎ウイルス塩基配列. 肝臓 51:536-538, 2010.
 
10) Takahashi M, et al:Analysis of the full-length genome of a hepatitis E virus isolate obtained from a wild boar in Japan that is classifiable into a novel genotype. J Gen Virol 92:902-908, 2011.
PubMed
11) Takahashi M, et al:Prolonged fecal shedding of hepatitis E virus(HEV) during sporadic acute hepa-titis E:evaluation of infectivity of HEV in fecal specimens in a cell culture system. J Clin Microbiol 45:3671-3679, 2007.
 
12) Tanaka T, et al:Development and characterization of a genotype 4 hepatitis E virus cell culture sys-tem using a HE-JF5/15F strain recovered from a fulminant hepatitis patient. J Clin Microbiol 47:1906-1910, 2009.
 
13) Yamada K, et al:Construction of an infectious cDNA clone of hepatitis E virus strain JE03-1760F that can propagate efficiently in cultured cells. J Gen Virol 90:457-462, 2009.
PubMed
14) Yamada K, et al:ORF3 protein of hepatitis E vinus is essential for virion release from infected cells.J Gen Virol 90:1880-1891, 2009.
 
15) Takahashi M, et al:Monoclonal antibodies raised against the ORF3 protein of hepatitis E virus(HEV) can capture HEV particles in culture supernatant and serum but not those in feces. Arch Virol 153:1703-1713, 2008.
 
16) Chandra C, et al:Molecular biology and pathogenesis of hepatitis E virus. J Biosci 33:451-464, 2008.
 
17) Nagashima S, et al:APSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells. J Gen Virol 92:269-278, 2011.
 
18) Purcell RH, Emerson SU:Animal models of hepatitis A and E. ILAR J 42:161-177, 2001.
 
P.592 掲載の参考文献
1) Takahashi K, et al:Full-genome nucleotide sequence of a hepatitis E virus strain that may be indigenous to Japan. Virology 287:9-12, 2001.
PubMed
2) Kwo PY, et al:Acute hepatitis E by a new isolate acquired in the United States. Mayo Clin Proc 72:1133-1136, 1997.
PubMed
3) Yano K, et al:Dynamic epidemiology of acute viral hepatitis in Japan. Intervirology 53:70-75, 2010.
PubMed
4) Matsubayashi K, et al:A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 48:1368-1375, 2008.
PubMed
5) 阿部敏紀ほか:本邦に於けるE型肝炎ウイルス感染の統計学的・疫学的・ウイルス学的特徴:全国集計254例に基づく解析. 肝臓 46:384-391, 2006.
 
6) 相川達也ほか:本邦初の妊婦に於ける3型土着株によるE型肝炎. 肝臓 50:163-165, 2009.
 
7) Lindermann ML et al:Low prevalence of hepatitis E infection among pregnant women in Madrid, Spain. J Med Virol 82:1666-1668, 2010.
 
8) Kamar N, et al:Hepatitis E virus and chronic hepatitis in organ-tansplant recipients. N Engl J Med 358:811-817, 2008.
 
9) le Coutre P, et al:Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut 58:699-702, 2009.
 
10) Haagsma EB, et al:Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl 16:474-477, 2010.
PubMed
11) Mallet V, et al:Brief communication:case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 153:85-89, 2010.
PubMed
12) Kamar N, et al:Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology 139:1612-1618, 2010.
PubMed
13) Shrestha MP, et al:Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 356:895-903, 2007.
PubMed
14) Zhu FC, et al:Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults:a large-scale, randomized, double blind placebo-controled, phase 3 trial. Lancet 376:895-902, 2010.
 
15) 大西幸代ほか:札幌地域E型肝炎症例におけるHEV感染リスクアンケート調査. 肝臓 47:163-164, 2006.
 

VI デルタ ( D型 ) 肝炎

P.599 掲載の参考文献
1) Rizzetto M, et al:Immunofluorescence detection of new antigen-antibody system(delta/antidelta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 18:997-1003, 1977.
 
2) Rizzetto M:The Delta agent. Hepatology 3:729-737, 1988.
 
3) Rizzetto M, et al:Epidemiology of HBV-associated delta agent:geographical distribution of antidelta and prevalence in polytransfused HBsAg carriers. Lancet i(8180):1215-1218, 1980.
 
4) Rizzetto M, Rosina F:Viral Hepatitis, 3rd ed, Section VI Hepatitis D virus epidemiology and natural history(ed by Thomas H), p583-592, Blackwell Science, Massachusetts, 2005.
 
5) 矢野右人, 井上長三:δ肝炎の臨床と日本における現況. 日本臨牀 47(3):715-720, 1989.
 
6) Iwanami E, et al:Local spread of HDV infection transiently occurring in Japan. J Gastroenterol Hepatol 8:565-568, 1993.
PubMed
7) Sakugawa H, et al:Seroepidemiological study on hepatitis delta virus infection in the Irabu Islands, Okinawa, Japan. J Gastroenterol Hepatol 12(4):299-304, 1997.
PubMed
8) 小方則夫ほか:デルタ(D型)肝炎ウイルス感染症.疫学, 感染様式, 臨床病像の概略 日本臨牀 62(増刊号8):406-411, 2004.
 
9) Gaeta GB, et al:Chronic hepatitisD:a vanishing disease? An ltalian Multicenter study. Hepatology 32:824-827, 2000.
 
10) Rizzetto M:Hepatitis D:the comeback? Liver Int 29(Suppl 1):140-142, 2009.
 
11) Casey JL, et al:A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci USA 90(19):9016-9020, 1993.
 
12) Wu JC, et al:Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 346(8980):939-941, 1995.
PubMed
13) Fattovich G, et al:Influence of hepatitis delta virus infection of morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis(Eurohep). Gut 46:420-426, 2000.
 
14) Anna G, et al:Viral Hepatitis, 3rd ed, Section VI Hepatitis D virus. Treatment(ed by Thomas H), p583-592, Blackwell Science, Massachusetts, 2005.
 
15) Gunsar F:Delta hepatitis. Expert Rev Anti Infect Ther 7(5)499-501, 2009.
PubMed
16) Castelnau C, et al:Efficacy of peginterferonα-2b in chronic hepatitis delta:relevance of quantitative RT-PCR for follow-up. Hepatology 44:728-735, 2006.
 
17) Niro GA, et al:Pegylated interferonα-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44:713-720, 2006.
 

書評

最近チェックした商品履歴

Loading...